ALT5 Sigma
ALTS
#9538
Rank
$0.11 B
Marketcap
$0.86
Share price
0.00%
Change (1 day)
-55.24%
Change (1 year)

ALT5 Sigma - 10-Q quarterly report FY2026 Q3


Text size:
falseQ3--12-260000862861http://ir.aifi.co/20260926#CryptoAssetWLFIMemberhttp://ir.aifi.co/20260926#CryptoAssetWLFIMemberhttp://ir.aifi.co/20260926#CryptoAssetWLFIMemberhttp://ir.aifi.co/20260926#AlyeaTherapeuticsCorporationMember00008628612025-12-282026-09-2600008628612026-11-0900008628612026-09-2600008628612025-12-270000862861AIFC:SeriesSPreferredStockMember2026-09-260000862861AIFC:SeriesSPreferredStockMember2025-12-270000862861us-gaap:SeriesAPreferredStockMember2026-09-260000862861us-gaap:SeriesAPreferredStockMember2025-12-270000862861us-gaap:SeriesBPreferredStockMember2026-09-260000862861us-gaap:SeriesBPreferredStockMember2025-12-270000862861AIFC:SeriesIConvertiblePreferredStockMember2026-09-260000862861AIFC:SeriesIConvertiblePreferredStockMember2025-12-270000862861AIFC:SeriesMPreferredStockMember2026-09-260000862861AIFC:SeriesMPreferredStockMember2025-12-270000862861AIFC:SeriesQPreferredStockMember2026-09-260000862861AIFC:SeriesQPreferredStockMember2025-12-270000862861AIFC:SeriesVConvertiblePreferredStockMember2026-09-260000862861AIFC:SeriesVConvertiblePreferredStockMember2025-12-2700008628612026-06-282026-09-2600008628612025-06-292025-09-2700008628612024-12-292025-09-2700008628612024-12-2800008628612025-09-270000862861us-gaap:PreferredStockMemberAIFC:SeriesA1ConvertiblePreferredStockMember2025-12-270000862861us-gaap:PreferredStockMemberAIFC:SeriesS1ConvertiblePreferredStockMember2025-12-270000862861us-gaap:PreferredStockMemberus-gaap:SeriesBPreferredStockMember2025-12-270000862861us-gaap:PreferredStockMemberAIFC:SeriesIConvertiblePreferredStockMember2025-12-270000862861us-gaap:PreferredStockMemberAIFC:SeriesMPreferredStockMember2025-12-270000862861us-gaap:PreferredStockMemberAIFC:SeriesQConvertiblePreferredStockMember2025-12-270000862861us-gaap:PreferredStockMemberAIFC:SeriesVConvertiblePreferredStockMember2025-12-270000862861us-gaap:CommonStockMember2025-12-270000862861us-gaap:AdditionalPaidInCapitalMember2025-12-270000862861us-gaap:TreasuryStockCommonMember2025-12-270000862861us-gaap:RetainedEarningsMember2025-12-270000862861us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-12-270000862861us-gaap:NoncontrollingInterestMember2025-12-270000862861us-gaap:PreferredStockMemberAIFC:SeriesA1ConvertiblePreferredStockMember2026-03-280000862861us-gaap:PreferredStockMemberAIFC:SeriesS1ConvertiblePreferredStockMember2026-03-280000862861us-gaap:PreferredStockMemberus-gaap:SeriesBPreferredStockMember2026-03-280000862861us-gaap:PreferredStockMemberAIFC:SeriesIConvertiblePreferredStockMember2026-03-280000862861us-gaap:PreferredStockMemberAIFC:SeriesMPreferredStockMember2026-03-280000862861us-gaap:PreferredStockMemberAIFC:SeriesQConvertiblePreferredStockMember2026-03-280000862861us-gaap:PreferredStockMemberAIFC:SeriesVConvertiblePreferredStockMember2026-03-280000862861us-gaap:CommonStockMember2026-03-280000862861us-gaap:AdditionalPaidInCapitalMember2026-03-280000862861us-gaap:TreasuryStockCommonMember2026-03-280000862861us-gaap:RetainedEarningsMember2026-03-280000862861us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-03-280000862861us-gaap:NoncontrollingInterestMember2026-03-2800008628612026-03-280000862861us-gaap:PreferredStockMemberAIFC:SeriesA1ConvertiblePreferredStockMember2026-06-270000862861us-gaap:PreferredStockMemberAIFC:SeriesS1ConvertiblePreferredStockMember2026-06-270000862861us-gaap:PreferredStockMemberus-gaap:SeriesBPreferredStockMember2026-06-270000862861us-gaap:PreferredStockMemberAIFC:SeriesIConvertiblePreferredStockMember2026-06-270000862861us-gaap:PreferredStockMemberAIFC:SeriesMPreferredStockMember2026-06-270000862861us-gaap:PreferredStockMemberAIFC:SeriesQConvertiblePreferredStockMember2026-06-270000862861us-gaap:PreferredStockMemberAIFC:SeriesVConvertiblePreferredStockMember2026-06-270000862861us-gaap:CommonStockMember2026-06-270000862861us-gaap:AdditionalPaidInCapitalMember2026-06-270000862861us-gaap:TreasuryStockCommonMember2026-06-270000862861us-gaap:RetainedEarningsMember2026-06-270000862861us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-06-270000862861us-gaap:NoncontrollingInterestMember2026-06-2700008628612026-06-270000862861us-gaap:PreferredStockMemberAIFC:SeriesA1ConvertiblePreferredStockMember2024-12-280000862861us-gaap:PreferredStockMemberAIFC:SeriesS1ConvertiblePreferredStockMember2024-12-280000862861us-gaap:PreferredStockMemberus-gaap:SeriesBPreferredStockMember2024-12-280000862861us-gaap:PreferredStockMemberAIFC:SeriesIConvertiblePreferredStockMember2024-12-280000862861us-gaap:PreferredStockMemberAIFC:SeriesMPreferredStockMember2024-12-280000862861us-gaap:PreferredStockMemberAIFC:SeriesQConvertiblePreferredStockMember2024-12-280000862861us-gaap:PreferredStockMemberAIFC:SeriesVConvertiblePreferredStockMember2024-12-280000862861us-gaap:CommonStockMember2024-12-280000862861us-gaap:AdditionalPaidInCapitalMember2024-12-280000862861us-gaap:RetainedEarningsMember2024-12-280000862861us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-280000862861us-gaap:NoncontrollingInterestMember2024-12-280000862861us-gaap:PreferredStockMemberAIFC:SeriesA1ConvertiblePreferredStockMember2025-03-290000862861us-gaap:PreferredStockMemberAIFC:SeriesS1ConvertiblePreferredStockMember2025-03-290000862861us-gaap:PreferredStockMemberus-gaap:SeriesBPreferredStockMember2025-03-290000862861us-gaap:PreferredStockMemberAIFC:SeriesIConvertiblePreferredStockMember2025-03-290000862861us-gaap:PreferredStockMemberAIFC:SeriesMPreferredStockMember2025-03-290000862861us-gaap:PreferredStockMemberAIFC:SeriesQConvertiblePreferredStockMember2025-03-290000862861us-gaap:PreferredStockMemberAIFC:SeriesVConvertiblePreferredStockMember2025-03-290000862861us-gaap:CommonStockMember2025-03-290000862861us-gaap:AdditionalPaidInCapitalMember2025-03-290000862861us-gaap:RetainedEarningsMember2025-03-290000862861us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-290000862861us-gaap:NoncontrollingInterestMember2025-03-2900008628612025-03-290000862861us-gaap:PreferredStockMemberAIFC:SeriesA1ConvertiblePreferredStockMember2025-06-280000862861us-gaap:PreferredStockMemberAIFC:SeriesS1ConvertiblePreferredStockMember2025-06-280000862861us-gaap:PreferredStockMemberus-gaap:SeriesBPreferredStockMember2025-06-280000862861us-gaap:PreferredStockMemberAIFC:SeriesIConvertiblePreferredStockMember2025-06-280000862861us-gaap:PreferredStockMemberAIFC:SeriesMPreferredStockMember2025-06-280000862861us-gaap:PreferredStockMemberAIFC:SeriesQConvertiblePreferredStockMember2025-06-280000862861us-gaap:PreferredStockMemberAIFC:SeriesVConvertiblePreferredStockMember2025-06-280000862861us-gaap:CommonStockMember2025-06-280000862861us-gaap:AdditionalPaidInCapitalMember2025-06-280000862861us-gaap:RetainedEarningsMember2025-06-280000862861us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-06-280000862861us-gaap:NoncontrollingInterestMember2025-06-2800008628612025-06-280000862861us-gaap:PreferredStockMemberAIFC:SeriesA1ConvertiblePreferredStockMember2025-12-282026-03-280000862861us-gaap:PreferredStockMemberAIFC:SeriesS1ConvertiblePreferredStockMember2025-12-282026-03-280000862861us-gaap:PreferredStockMemberus-gaap:SeriesBPreferredStockMember2025-12-282026-03-280000862861us-gaap:PreferredStockMemberAIFC:SeriesIConvertiblePreferredStockMember2025-12-282026-03-280000862861us-gaap:PreferredStockMemberAIFC:SeriesMPreferredStockMember2025-12-282026-03-280000862861us-gaap:PreferredStockMemberAIFC:SeriesQConvertiblePreferredStockMember2025-12-282026-03-280000862861us-gaap:PreferredStockMemberAIFC:SeriesVConvertiblePreferredStockMember2025-12-282026-03-280000862861us-gaap:CommonStockMember2025-12-282026-03-280000862861us-gaap:AdditionalPaidInCapitalMember2025-12-282026-03-280000862861us-gaap:TreasuryStockCommonMember2025-12-282026-03-280000862861us-gaap:RetainedEarningsMember2025-12-282026-03-280000862861us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-12-282026-03-280000862861us-gaap:NoncontrollingInterestMember2025-12-282026-03-2800008628612025-12-282026-03-280000862861us-gaap:PreferredStockMemberAIFC:SeriesA1ConvertiblePreferredStockMember2026-03-292026-06-270000862861us-gaap:PreferredStockMemberAIFC:SeriesS1ConvertiblePreferredStockMember2026-03-292026-06-270000862861us-gaap:PreferredStockMemberus-gaap:SeriesBPreferredStockMember2026-03-292026-06-270000862861us-gaap:PreferredStockMemberAIFC:SeriesIConvertiblePreferredStockMember2026-03-292026-06-270000862861us-gaap:PreferredStockMemberAIFC:SeriesMPreferredStockMember2026-03-292026-06-270000862861us-gaap:PreferredStockMemberAIFC:SeriesQConvertiblePreferredStockMember2026-03-292026-06-270000862861us-gaap:PreferredStockMemberAIFC:SeriesVConvertiblePreferredStockMember2026-03-292026-06-270000862861us-gaap:CommonStockMember2026-03-292026-06-270000862861us-gaap:AdditionalPaidInCapitalMember2026-03-292026-06-270000862861us-gaap:TreasuryStockCommonMember2026-03-292026-06-270000862861us-gaap:RetainedEarningsMember2026-03-292026-06-270000862861us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-03-292026-06-270000862861us-gaap:NoncontrollingInterestMember2026-03-292026-06-2700008628612026-03-292026-06-270000862861us-gaap:PreferredStockMemberAIFC:SeriesA1ConvertiblePreferredStockMember2026-06-282026-09-260000862861us-gaap:PreferredStockMemberAIFC:SeriesS1ConvertiblePreferredStockMember2026-06-282026-09-260000862861us-gaap:PreferredStockMemberus-gaap:SeriesBPreferredStockMember2026-06-282026-09-260000862861us-gaap:PreferredStockMemberAIFC:SeriesIConvertiblePreferredStockMember2026-06-282026-09-260000862861us-gaap:PreferredStockMemberAIFC:SeriesMPreferredStockMember2026-06-282026-09-260000862861us-gaap:PreferredStockMemberAIFC:SeriesQConvertiblePreferredStockMember2026-06-282026-09-260000862861us-gaap:PreferredStockMemberAIFC:SeriesVConvertiblePreferredStockMember2026-06-282026-09-260000862861us-gaap:CommonStockMember2026-06-282026-09-260000862861us-gaap:AdditionalPaidInCapitalMember2026-06-282026-09-260000862861us-gaap:TreasuryStockCommonMember2026-06-282026-09-260000862861us-gaap:RetainedEarningsMember2026-06-282026-09-260000862861us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-06-282026-09-260000862861us-gaap:NoncontrollingInterestMember2026-06-282026-09-260000862861us-gaap:PreferredStockMemberAIFC:SeriesA1ConvertiblePreferredStockMember2024-12-292025-03-290000862861us-gaap:PreferredStockMemberAIFC:SeriesS1ConvertiblePreferredStockMember2024-12-292025-03-290000862861us-gaap:PreferredStockMemberus-gaap:SeriesBPreferredStockMember2024-12-292025-03-290000862861us-gaap:PreferredStockMemberAIFC:SeriesIConvertiblePreferredStockMember2024-12-292025-03-290000862861us-gaap:PreferredStockMemberAIFC:SeriesMPreferredStockMember2024-12-292025-03-290000862861us-gaap:PreferredStockMemberAIFC:SeriesQConvertiblePreferredStockMember2024-12-292025-03-290000862861us-gaap:PreferredStockMemberAIFC:SeriesVConvertiblePreferredStockMember2024-12-292025-03-290000862861us-gaap:CommonStockMember2024-12-292025-03-290000862861us-gaap:AdditionalPaidInCapitalMember2024-12-292025-03-290000862861us-gaap:RetainedEarningsMember2024-12-292025-03-290000862861us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-292025-03-290000862861us-gaap:NoncontrollingInterestMember2024-12-292025-03-2900008628612024-12-292025-03-290000862861us-gaap:PreferredStockMemberAIFC:SeriesA1ConvertiblePreferredStockMember2025-03-302025-06-280000862861us-gaap:PreferredStockMemberAIFC:SeriesS1ConvertiblePreferredStockMember2025-03-302025-06-280000862861us-gaap:PreferredStockMemberus-gaap:SeriesBPreferredStockMember2025-03-302025-06-280000862861us-gaap:PreferredStockMemberAIFC:SeriesIConvertiblePreferredStockMember2025-03-302025-06-280000862861us-gaap:PreferredStockMemberAIFC:SeriesMPreferredStockMember2025-03-302025-06-280000862861us-gaap:PreferredStockMemberAIFC:SeriesQConvertiblePreferredStockMember2025-03-302025-06-280000862861us-gaap:PreferredStockMemberAIFC:SeriesVConvertiblePreferredStockMember2025-03-302025-06-280000862861us-gaap:CommonStockMember2025-03-302025-06-280000862861us-gaap:AdditionalPaidInCapitalMember2025-03-302025-06-280000862861us-gaap:RetainedEarningsMember2025-03-302025-06-280000862861us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-302025-06-280000862861us-gaap:NoncontrollingInterestMember2025-03-302025-06-2800008628612025-03-302025-06-280000862861us-gaap:PreferredStockMemberAIFC:SeriesA1ConvertiblePreferredStockMember2025-06-292025-09-270000862861us-gaap:PreferredStockMemberAIFC:SeriesS1ConvertiblePreferredStockMember2025-06-292025-09-270000862861us-gaap:PreferredStockMemberus-gaap:SeriesBPreferredStockMember2025-06-292025-09-270000862861us-gaap:PreferredStockMemberAIFC:SeriesIConvertiblePreferredStockMember2025-06-292025-09-270000862861us-gaap:PreferredStockMemberAIFC:SeriesMPreferredStockMember2025-06-292025-09-270000862861us-gaap:PreferredStockMemberAIFC:SeriesQConvertiblePreferredStockMember2025-06-292025-09-270000862861us-gaap:PreferredStockMemberAIFC:SeriesVConvertiblePreferredStockMember2025-06-292025-09-270000862861us-gaap:CommonStockMember2025-06-292025-09-270000862861us-gaap:AdditionalPaidInCapitalMember2025-06-292025-09-270000862861us-gaap:RetainedEarningsMember2025-06-292025-09-270000862861us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-06-292025-09-270000862861us-gaap:NoncontrollingInterestMember2025-06-292025-09-270000862861us-gaap:PreferredStockMemberAIFC:SeriesA1ConvertiblePreferredStockMember2026-09-260000862861us-gaap:PreferredStockMemberAIFC:SeriesS1ConvertiblePreferredStockMember2026-09-260000862861us-gaap:PreferredStockMemberus-gaap:SeriesBPreferredStockMember2026-09-260000862861us-gaap:PreferredStockMemberAIFC:SeriesIConvertiblePreferredStockMember2026-09-260000862861us-gaap:PreferredStockMemberAIFC:SeriesMPreferredStockMember2026-09-260000862861us-gaap:PreferredStockMemberAIFC:SeriesQConvertiblePreferredStockMember2026-09-260000862861us-gaap:PreferredStockMemberAIFC:SeriesVConvertiblePreferredStockMember2026-09-260000862861us-gaap:CommonStockMember2026-09-260000862861us-gaap:AdditionalPaidInCapitalMember2026-09-260000862861us-gaap:TreasuryStockCommonMember2026-09-260000862861us-gaap:RetainedEarningsMember2026-09-260000862861us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-09-260000862861us-gaap:NoncontrollingInterestMember2026-09-260000862861us-gaap:PreferredStockMemberAIFC:SeriesA1ConvertiblePreferredStockMember2025-09-270000862861us-gaap:PreferredStockMemberAIFC:SeriesS1ConvertiblePreferredStockMember2025-09-270000862861us-gaap:PreferredStockMemberus-gaap:SeriesBPreferredStockMember2025-09-270000862861us-gaap:PreferredStockMemberAIFC:SeriesIConvertiblePreferredStockMember2025-09-270000862861us-gaap:PreferredStockMemberAIFC:SeriesMPreferredStockMember2025-09-270000862861us-gaap:PreferredStockMemberAIFC:SeriesQConvertiblePreferredStockMember2025-09-270000862861us-gaap:PreferredStockMemberAIFC:SeriesVConvertiblePreferredStockMember2025-09-270000862861us-gaap:CommonStockMember2025-09-270000862861us-gaap:AdditionalPaidInCapitalMember2025-09-270000862861us-gaap:RetainedEarningsMember2025-09-270000862861us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-09-270000862861us-gaap:NoncontrollingInterestMember2025-09-2700008628612025-08-120000862861AIFC:CryptoTreasuryProgramTrancheOneMember2025-08-1200008628612025-08-122025-08-120000862861AIFC:CryptoTreasuryProgramTrancheTwoMember2025-08-120000862861AIFC:TokenPurchaseAgreementMember2026-09-260000862861AIFC:SecuritiesPurchaseAgreementMember2026-09-260000862861AIFC:PreFundedWarrantsMember2025-08-122025-08-120000862861AIFC:PreFundedWarrantsMembersrt:MaximumMember2025-08-120000862861AIFC:PreFundedWarrantsMember2025-08-120000862861us-gaap:NotesPayableOtherPayablesMember2026-09-260000862861us-gaap:NotesPayableOtherPayablesMember2025-12-270000862861AIFC:StockExchangeAgreementMemberAIFC:BlockStreetCorpMember2026-04-200000862861AIFC:BlockStreetCorpMemberus-gaap:CommonStockMember2026-04-202026-04-200000862861AIFC:BlockStreetCorpMemberus-gaap:CommonStockMember2026-04-200000862861AIFC:BlockStreetCorpMemberus-gaap:CommonStockMemberAIFC:FirstEarnoutMember2026-04-202026-04-200000862861AIFC:BlockStreetCorpMemberAIFC:FirstEarnoutMember2026-04-200000862861AIFC:BlockStreetCorpMemberAIFC:SecondEarnoutMember2026-04-202026-04-200000862861AIFC:BlockStreetCorpMemberus-gaap:CommonStockMemberAIFC:SecondEarnoutMember2026-04-202026-04-200000862861AIFC:BlockStreetCorpMemberAIFC:SecondEarnoutMember2026-04-200000862861AIFC:BlockStreetCorpMember2026-04-202026-04-200000862861AIFC:ThreeSellersMemberAIFC:MswipeTransactionMember2025-05-092025-05-090000862861AIFC:ThreeSellersMemberAIFC:MswipeTransactionMember2025-05-090000862861AIFC:ThreeSellersMember2025-05-090000862861AIFC:TwoOfTheSellersMemberAIFC:MswipeTransactionMember2025-05-090000862861AIFC:TwoOfTheSellersMemberAIFC:MswipeTransactionMember2025-05-092025-05-090000862861AIFC:MswipeTransactionMember2025-05-090000862861AIFC:MswipeTransactionMember2025-05-092025-05-0900008628612025-05-090000862861AIFC:BlockStreetMember2025-12-282026-09-260000862861AIFC:MswipeAcquisitionMember2025-12-282026-09-260000862861AIFC:BlockStreetCorpMemberus-gaap:CommonStockMemberAIFC:ALT5CommonStockMember2026-04-202026-04-200000862861AIFC:BlockStreetCorpMember2026-04-200000862861AIFC:MswipeTransactionMember2026-04-200000862861AIFC:MswipeAcquisitionMemberus-gaap:CommonStockMemberAIFC:ALT5CommonStockMember2025-05-092025-05-090000862861AIFC:MswipeAcquisitionMemberAIFC:WarrantsMember2025-05-092025-05-090000862861AIFC:MswipeAcquisitionMemberAIFC:SellerNotesMember2025-05-092025-05-090000862861AIFC:MswipeAcquisitionMemberAIFC:DrewCommonStockMember2025-05-092025-05-090000862861AIFC:MswipeAcquisitionMember2025-05-092025-05-090000862861us-gaap:CustomerRelationshipsMemberAIFC:MswipeTransactionMember2025-05-090000862861us-gaap:TradeNamesMemberAIFC:MswipeTransactionMember2025-05-090000862861us-gaap:DevelopedTechnologyRightsMemberAIFC:MswipeTransactionMember2025-05-090000862861AIFC:AIFinancialCorporationMember2025-06-292025-09-270000862861AIFC:MswipeMember2025-06-292025-09-270000862861us-gaap:ScenarioAdjustmentMember2025-06-292025-09-270000862861srt:ProFormaMember2025-06-292025-09-270000862861AIFC:AIFinancialCorporationMember2024-12-292025-09-270000862861AIFC:MswipeMember2024-12-292025-09-270000862861us-gaap:ScenarioAdjustmentMember2024-12-292025-09-270000862861srt:ProFormaMember2024-12-292025-09-270000862861us-gaap:SegmentDiscontinuedOperationsMemberAIFC:AlyeaTherapeuticsCorporationMember2026-09-260000862861us-gaap:SegmentDiscontinuedOperationsMemberAIFC:AlyeaTherapeuticsCorporationMember2025-12-270000862861us-gaap:SegmentDiscontinuedOperationsMemberAIFC:AlyeaTherapeuticsCorporationMemberus-gaap:BuildingImprovementsMember2026-09-260000862861us-gaap:SegmentDiscontinuedOperationsMemberAIFC:AlyeaTherapeuticsCorporationMemberus-gaap:BuildingImprovementsMember2025-12-270000862861us-gaap:SegmentDiscontinuedOperationsMemberAIFC:AlyeaTherapeuticsCorporationMemberAIFC:SoinIntangibleMember2026-09-260000862861us-gaap:SegmentDiscontinuedOperationsMemberAIFC:AlyeaTherapeuticsCorporationMemberAIFC:SoinIntangibleMember2025-12-270000862861us-gaap:SegmentDiscontinuedOperationsMemberAIFC:SoinTherapeuticsLLCMemberAIFC:DrSoinMember2026-09-260000862861us-gaap:SegmentDiscontinuedOperationsMemberAIFC:SoinTherapeuticsLLCMemberAIFC:DrSoinMember2025-12-270000862861us-gaap:SegmentDiscontinuedOperationsMemberAIFC:SoinTherapeuticsLLCMemberAIFC:ALT5CanadaMember2026-09-260000862861us-gaap:SegmentDiscontinuedOperationsMemberAIFC:SoinTherapeuticsLLCMemberAIFC:ALT5CanadaMember2025-12-270000862861us-gaap:SegmentDiscontinuedOperationsMemberAIFC:SoinTherapeuticsLLCMember2026-09-260000862861us-gaap:SegmentDiscontinuedOperationsMemberAIFC:SoinTherapeuticsLLCMember2025-12-270000862861us-gaap:SegmentDiscontinuedOperationsMemberAIFC:BiotechSegmentMember2026-06-282026-09-260000862861us-gaap:SegmentDiscontinuedOperationsMemberAIFC:BiotechSegmentMember2025-06-292025-09-270000862861us-gaap:SegmentDiscontinuedOperationsMemberAIFC:BiotechSegmentMember2025-12-282026-09-260000862861us-gaap:SegmentDiscontinuedOperationsMemberAIFC:BiotechSegmentMember2024-12-292025-09-270000862861AIFC:SoinIntangiblesMember2022-12-280000862861AIFC:AcquisitionAgreementMember2026-07-292026-07-290000862861AIFC:AcquisitionAgreementMember2026-07-290000862861AIFC:AcquisitionAgreementMember2026-08-112026-08-1100008628612026-07-292026-07-290000862861AIFC:AcquisitionAgreementMemberus-gaap:ScenarioAdjustmentMember2026-07-290000862861AIFC:AcquisitionAgreementMemberus-gaap:SeriesBPreferredStockMember2026-07-292026-07-290000862861us-gaap:EquipmentMember2026-09-260000862861us-gaap:EquipmentMember2025-12-270000862861us-gaap:ComputerEquipmentMember2026-09-260000862861us-gaap:ComputerEquipmentMember2025-12-270000862861AIFC:CryptoAssetWLFIMember2025-08-120000862861AIFC:TrancheOneMemberAIFC:CryptoAssetWLFIMember2025-08-120000862861AIFC:CryptoAssetWLFIMemberAIFC:TrancheTwoMember2025-08-120000862861AIFC:CryptoAssetWLFIMemberAIFC:TrancheOneMember2025-08-120000862861AIFC:ConcreteNetworkServicesLtdMember2026-09-260000862861AIFC:ConcreteNetworkServicesLtdMember2026-08-030000862861AIFC:ConcreteNetworkServicesLtdMember2026-07-130000862861AIFC:ConcreteNetworkServicesLtdMemberAIFC:PledgedMember2026-09-260000862861AIFC:ConcreteNetworkServicesLtdMemberus-gaap:CollateralizedLoanObligationsMember2026-09-260000862861AIFC:ConcreteNetworkServicesLtdMemberAIFC:UnpledgedMember2026-09-260000862861AIFC:ConcreteNetworkServicesLtdMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2026-09-260000862861AIFC:CryptoAssetWLFIMember2026-09-260000862861us-gaap:NoncompeteAgreementsMember2026-09-260000862861us-gaap:NoncompeteAgreementsMember2025-12-270000862861AIFC:CryptocurrencyExchangeSoftwareIntangibleMember2026-09-260000862861AIFC:CryptocurrencyExchangeSoftwareIntangibleMember2025-12-270000862861AIFC:PatentsAndDomainsMember2026-09-260000862861AIFC:PatentsAndDomainsMember2025-12-270000862861us-gaap:TradeNamesMember2026-09-260000862861us-gaap:TradeNamesMember2025-12-270000862861us-gaap:CustomerRelationshipsMember2026-09-260000862861us-gaap:CustomerRelationshipsMember2025-12-270000862861AIFC:BlockStreetIntangibleMember2026-09-260000862861AIFC:BlockStreetIntangibleMember2025-12-270000862861us-gaap:DevelopedTechnologyRightsMember2026-09-260000862861us-gaap:DevelopedTechnologyRightsMember2025-12-270000862861AIFC:QodenTechnologiesLLCMemberAIFC:QodenIntangibleMember2024-11-080000862861AIFC:ALT5SubsidiaryMemberus-gaap:TradeNamesMember2024-05-140000862861AIFC:ALT5SubsidiaryMemberus-gaap:CustomerRelationshipsMember2024-05-140000862861AIFC:ALT5SubsidiaryMemberus-gaap:DevelopedTechnologyRightsMember2024-05-140000862861AIFC:FintechMember2025-12-270000862861AIFC:BiotechnologyMember2025-12-270000862861AIFC:CorporateAndOtherSegmentMember2025-12-270000862861AIFC:FintechMember2025-12-282026-09-260000862861AIFC:BiotechnologyMember2025-12-282026-09-260000862861AIFC:CorporateAndOtherSegmentMember2025-12-282026-09-260000862861AIFC:FintechMember2026-09-260000862861AIFC:BiotechnologyMember2026-09-260000862861AIFC:CorporateAndOtherSegmentMember2026-09-2600008628612024-12-292025-12-2700008628612024-12-292026-12-270000862861AIFC:A12DebenturesMaturingJune302025MemberAIFC:DebenturesMember2026-09-260000862861AIFC:A12DebenturesMaturingJune302025MemberAIFC:DebenturesMember2025-12-2700008628612018-10-012019-09-3000008628612026-03-012026-03-310000862861AIFC:MasterServicesAgreementMember2026-09-260000862861AIFC:MasterServicesAgreementMember2026-08-030000862861AIFC:LegacySubsidiaryFixedDepositsMemberAIFC:FixedDepositAgreementMemberAIFC:ALT5SubsidiaryMembersrt:MinimumMember2026-09-260000862861AIFC:LegacySubsidiaryFixedDepositsMemberAIFC:FixedDepositAgreementMemberAIFC:ALT5SubsidiaryMembersrt:MaximumMember2026-09-260000862861AIFC:LegacySubsidiaryFixedDepositsMemberAIFC:FixedDepositAgreementMemberAIFC:ALT5SubsidiaryMember2026-09-260000862861AIFC:LegacySubsidiaryFixedDepositsMemberAIFC:FixedDepositAgreementMemberAIFC:ALT5SubsidiaryMember2025-12-270000862861AIFC:InsurancePremiumFinancingMemberus-gaap:RelatedPartyMember2026-09-260000862861AIFC:WLFILoanAgreementMember2026-01-290000862861AIFC:LtvLessThan65PercentMemberAIFC:WLFILoanAgreementMember2026-01-290000862861AIFC:WLFILoanAgreementMemberAIFC:LoanMember2026-01-290000862861AIFC:WLFILoanAgreementMemberAIFC:UnrestrictedWLFITokensMember2026-01-290000862861AIFC:WLFILoanAgreementMember2026-01-292026-01-290000862861AIFC:WLFILoanAgreementMember2026-03-280000862861AIFC:WLFILoanAgreementMember2026-09-260000862861AIFC:ICGNoteMemberAIFC:PromissoryNoteMemberAIFC:NotesPayableWithLiveVenturesAndICGMemberus-gaap:RelatedPartyMember2024-02-070000862861AIFC:ICGNoteMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:RelatedPartyMember2024-02-070000862861AIFC:ICGNoteMemberAIFC:PromissoryNoteMemberAIFC:NotesPayableWithLiveVenturesAndICGMemberus-gaap:RelatedPartyMember2025-09-270000862861AIFC:ICGNoteMemberAIFC:PromissoryNoteMemberAIFC:NotesPayableWithLiveVenturesAndICGMemberus-gaap:RelatedPartyMember2024-12-292025-09-270000862861AIFC:ICGNoteMemberAIFC:PromissoryNoteMemberAIFC:NotesPayableWithLiveVenturesAndICGMemberus-gaap:RelatedPartyMember2026-09-260000862861AIFC:ICGNoteMemberAIFC:PromissoryNoteMemberAIFC:NotesPayableWithLiveVenturesAndICGMemberus-gaap:RelatedPartyMember2025-12-270000862861AIFC:NonConvertibleDebentureBigDebentureMemberus-gaap:UnsecuredDebtMember2024-08-200000862861AIFC:NonConvertibleDebentureBigDebentureMemberus-gaap:UnsecuredDebtMemberAIFC:InvestorOneMember2024-08-200000862861AIFC:BigWarrantMemberAIFC:InvestorOneMember2024-08-200000862861AIFC:BigWarrantMemberAIFC:InvestorTwoAndInvestorThreeMemberAIFC:NonConvertibleDebentureSmallDebentureMemberus-gaap:UnsecuredDebtMember2024-08-200000862861us-gaap:WarrantMemberAIFC:InvestorTwoAndInvestorThreeMember2024-08-200000862861us-gaap:UnsecuredDebtMemberAIFC:InvestorTwoAndInvestorThreeMemberAIFC:DebtInstrumentCovenantPeriodPeriodOneMember2024-08-200000862861us-gaap:UnsecuredDebtMemberAIFC:DebtInstrumentCovenantPeriodPeriodTwoMemberAIFC:NonConvertibleDebentureBigAndSmallDebentureMember2024-08-200000862861us-gaap:UnsecuredDebtMemberAIFC:DebtInstrumentCovenantPeriodPeriodThreeMemberAIFC:NonConvertibleDebentureBigAndSmallDebentureMember2024-08-200000862861us-gaap:UnsecuredDebtMemberAIFC:NonConvertibleDebentureBigDebenturesMember2024-08-200000862861AIFC:UnsecuredDebtTwoMemberAIFC:NonConvertibleDebentureBigDebentureMember2024-08-200000862861us-gaap:UnsecuredDebtMemberAIFC:NonConvertibleDebentureBigDebentureMemberAIFC:DebtInstrumentOriginalIssueDiscountExpansionOneMember2024-08-200000862861us-gaap:UnsecuredDebtMemberAIFC:NonConvertibleDebentureBigDebentureMemberAIFC:DebtInstrumentOriginalIssueDiscountExpansionTwoMember2024-08-200000862861us-gaap:UnsecuredDebtMemberAIFC:NonConvertibleDebentureSmallDebentureMember2024-08-200000862861us-gaap:UnsecuredDebtMemberAIFC:NonConvertibleDebentureSmallDebentureMemberAIFC:DebtInstrumentOriginalIssueDiscountExpansionOneMember2024-08-200000862861us-gaap:UnsecuredDebtMemberAIFC:NonConvertibleDebentureSmallDebentureMemberAIFC:DebtInstrumentOriginalIssueDiscountExpansionTwoMember2024-08-200000862861AIFC:NonConvertibleDebentureSmallDebentureMemberus-gaap:UnsecuredDebtMember2024-11-010000862861AIFC:BigWarrantMember2024-08-200000862861AIFC:BigWarrantMemberAIFC:DebtInstrumentCovenantPeriodPeriodOneMember2024-08-200000862861AIFC:BigWarrantMemberAIFC:DebtInstrumentCovenantPeriodPeriodTwoMember2024-08-200000862861AIFC:BigWarrantMemberAIFC:DebtInstrumentCovenantPeriodPeriodThreeMember2024-08-200000862861AIFC:SmallWarrantMember2024-08-200000862861AIFC:SmallWarrantMemberAIFC:DebtInstrumentCovenantPeriodPeriodOneMember2024-08-200000862861AIFC:SmallWarrantMemberAIFC:DebtInstrumentCovenantPeriodPeriodTwoMember2024-10-310000862861AIFC:SmallWarrantMemberAIFC:DebtInstrumentCovenantPeriodPeriodThreeMember2024-08-2000008628612024-08-202024-08-2000008628612024-08-200000862861AIFC:NonConvertibleDebentureSmallDebentureMember2025-06-292025-09-270000862861AIFC:BigWarrantMemberus-gaap:RelatedPartyMember2024-09-292024-12-280000862861AIFC:SmallWarrantMemberus-gaap:RelatedPartyMember2024-09-292024-12-280000862861AIFC:NonConvertibleDebentureBigAndSmallDebentureMemberus-gaap:UnsecuredDebtMember2024-09-292024-12-280000862861AIFC:NonConvertibleDebentureBigAndSmallDebentureMemberus-gaap:UnsecuredDebtMember2025-06-292025-09-270000862861AIFC:NonConvertibleDebentureBigAndSmallDebentureMemberus-gaap:UnsecuredDebtMember2026-06-260000862861AIFC:NonConvertibleDebentureBigAndSmallDebentureMemberus-gaap:UnsecuredDebtMember2025-12-270000862861AIFC:ExtensionsAndFirstAmendmentAgreementsMember2026-07-070000862861AIFC:ExtensionsAndFirstAmendmentAgreementsMember2026-07-072026-07-070000862861AIFC:ExtensionsAndFirstAmendmentAgreementsMembersrt:MaximumMember2026-07-070000862861AIFC:ExtensionsAndFirstAmendmentAgreementsMembersrt:MinimumMember2026-07-070000862861AIFC:FixedDepositsMemberus-gaap:RelatedPartyMember2026-09-260000862861AIFC:FixedDepositsMemberus-gaap:RelatedPartyMember2025-12-270000862861AIFC:WLFILoanMemberus-gaap:RelatedPartyMember2026-09-260000862861AIFC:WLFILoanMemberus-gaap:RelatedPartyMember2025-12-270000862861AIFC:LegacyUnaffiliatedThirdPartyNotesMemberus-gaap:RelatedPartyMember2026-09-260000862861AIFC:LegacyUnaffiliatedThirdPartyNotesMemberus-gaap:RelatedPartyMember2025-12-270000862861AIFC:LegacySellerNotesMemberus-gaap:RelatedPartyMember2026-09-260000862861AIFC:LegacySellerNotesMemberus-gaap:RelatedPartyMember2025-12-270000862861AIFC:ConcreteClientAdvanceMemberus-gaap:RelatedPartyMember2026-09-260000862861AIFC:ConcreteClientAdvanceMemberus-gaap:RelatedPartyMember2025-12-270000862861AIFC:InsurancePremiumFinancingMemberus-gaap:RelatedPartyMember2025-12-270000862861us-gaap:RelatedPartyMember2026-09-260000862861us-gaap:RelatedPartyMember2025-12-270000862861AIFC:SECComplaintMember2024-05-282024-05-2800008628612026-08-262026-08-2600008628612026-11-012026-11-3000008628612026-12-012026-12-310000862861srt:ScenarioForecastMember2027-01-012027-01-310000862861srt:ScenarioForecastMember2029-05-012029-05-310000862861AIFC:GulfCoastBankAndTrustMember2025-12-282026-09-260000862861AIFC:GulfCoastBankAndTrustMember2025-12-012025-12-010000862861AIFC:GulfCoastBankAndTrustMemberus-gaap:CashMember2025-12-012025-12-010000862861AIFC:InreVirlandJohnsonMemberus-gaap:RestrictedStockUnitsRSUMember2023-10-012023-10-310000862861AIFC:FirstCapitalConsultingIncDBATrusaicvsALT5SigmaCorporationMember2025-12-282026-09-2600008628612026-10-012026-10-300000862861AIFC:RwandaLitigationMember2025-05-070000862861AIFC:OtherCommitmentsAndLitigationCasesMember2017-12-300000862861AIFC:OtherCommitmentsAndLitigationCasesMember2024-12-280000862861AIFC:RegisteredDirectOfferingMember2025-08-122025-08-120000862861AIFC:RegisteredDirectOfferingMember2025-08-120000862861us-gaap:PrivatePlacementMember2025-08-122025-08-120000862861us-gaap:PrivatePlacementMember2025-08-120000862861us-gaap:PrivatePlacementMemberAIFC:PreFundedWarrantsMember2025-08-120000862861us-gaap:PrivatePlacementMemberAIFC:PreFundedWarrantsMember2025-08-122025-08-120000862861us-gaap:PrivatePlacementMemberAIFC:LeadInvestorWarrantsMember2025-08-120000862861us-gaap:PrivatePlacementMemberAIFC:LeadInvestorWarrantsMemberAIFC:FirstCommitmentsMember2025-08-120000862861us-gaap:PrivatePlacementMemberAIFC:LeadInvestorWarrantsMemberAIFC:SecondCommitmentsMember2025-08-120000862861us-gaap:PrivatePlacementMemberAIFC:LeadInvestorWarrantsMemberAIFC:ThirdCommitmentsMember2025-08-120000862861us-gaap:PrivatePlacementMemberAIFC:LeadInvestorWarrantsMemberAIFC:FourthCommitmentsMember2025-08-120000862861AIFC:RegisteredDirectOfferingMemberAIFC:AllianceGlobalPartnersMember2025-08-110000862861AIFC:RegisteredDirectOfferingMemberAIFC:AllianceGlobalPartnersMemberAIFC:PlacementAgentWarrantsMember2025-08-110000862861AIFC:RegisteredDirectOfferingMemberAIFC:AllianceGlobalPartnersMemberAIFC:PlacementAgentWarrantsMember2025-08-112025-08-110000862861us-gaap:PrivatePlacementMemberAIFC:AllianceGlobalPartnersMember2025-08-112025-08-110000862861us-gaap:PrivatePlacementMemberAIFC:AllianceGlobalPartnersMember2025-08-110000862861us-gaap:PrivatePlacementMemberAIFC:AllianceGlobalPartnersMemberAIFC:PlacementAgentWarrantsMember2025-08-110000862861us-gaap:PrivatePlacementMemberAIFC:AllianceGlobalPartnersMemberAIFC:PlacementAgentWarrantsMember2025-08-112025-08-110000862861us-gaap:PrivatePlacementMemberAIFC:AllianceGlobalPartnersMember2025-12-302025-12-300000862861us-gaap:PrivatePlacementMemberAIFC:AllianceGlobalPartnersMember2025-12-300000862861us-gaap:PrivatePlacementMemberAIFC:AllianceGlobalPartnersMember2025-12-262025-12-2600008628612025-08-112025-08-1100008628612025-08-110000862861AIFC:ArticlesOfIncorporationMember2026-09-260000862861AIFC:ArticlesOfIncorporationMember2025-09-270000862861AIFC:BlockStreetCorpMember2025-12-282026-09-260000862861AIFC:EquityIncentivePlanMember2024-12-292025-09-270000862861AIFC:ThirdPartyExchangeForBrokerageServicesMemberus-gaap:NonrelatedPartyMember2024-12-292025-09-270000862861srt:PresidentMemberus-gaap:RestrictedStockUnitsRSUMember2024-12-292025-09-270000862861srt:PresidentMemberus-gaap:RestrictedStockUnitsRSUMemberAIFC:TwoThousandTwentyFourPlanMember2024-12-292025-09-270000862861srt:PresidentMemberus-gaap:RestrictedStockUnitsRSUMemberAIFC:TwoThousandTwentyThreePlanMember2024-12-292025-09-270000862861srt:PresidentMember2024-12-292025-09-270000862861us-gaap:RelatedPartyMemberAIFC:ICGNoteMemberAIFC:PromissoryNoteMember2024-12-292025-09-270000862861us-gaap:RelatedPartyMemberAIFC:ICGNoteMemberus-gaap:EquityUnitPurchaseAgreementsMember2024-12-292025-09-270000862861us-gaap:RelatedPartyMemberAIFC:LiveNoteMemberAIFC:PromissoryNoteMember2024-12-292025-09-270000862861us-gaap:RelatedPartyMemberAIFC:LiveNoteMemberus-gaap:EquityUnitPurchaseAgreementsMember2024-12-292025-09-270000862861us-gaap:RelatedPartyMemberAIFC:ICGNoteMemberAIFC:PromissoryNoteMember2025-05-152025-05-150000862861us-gaap:RelatedPartyMember2025-05-022025-05-020000862861AIFC:NonConvertibleDebentureSmallDebentureMember2024-12-292025-12-270000862861AIFC:SeriesVPreferredStockMemberAIFC:UnaffiliatedThirdPartyMember2024-05-042024-05-040000862861AIFC:SeriesVConvertiblePreferredStockMember2025-03-1200008628612025-01-152025-01-150000862861AIFC:A2024EquityIncentivePlanMember2026-06-270000862861AIFC:A2023EquityIncentivePlanMember2026-09-260000862861AIFC:A2023EquityIncentivePlanMemberus-gaap:RestrictedStockUnitsRSUMember2025-12-282026-09-260000862861AIFC:A2023EquityIncentivePlanMemberus-gaap:RestrictedStockUnitsRSUMember2024-12-292025-09-270000862861AIFC:Plan2016Member2020-11-030000862861AIFC:Plan2016Member2020-11-040000862861AIFC:Plan2016Member2026-09-260000862861AIFC:Plan2016Member2025-12-270000862861AIFC:Plan2011Member2026-09-260000862861AIFC:Plan2011Member2025-12-270000862861AIFC:ShareBasedPaymentArrangementOptionMember2026-06-282026-09-260000862861AIFC:ShareBasedPaymentArrangementOptionMember2025-06-292025-09-270000862861AIFC:ShareBasedPaymentArrangementOptionMember2025-12-282026-09-260000862861AIFC:ShareBasedPaymentArrangementOptionMember2024-12-292025-09-270000862861AIFC:ShareBasedPaymentArrangementOptionMember2026-09-260000862861AIFC:SeriesIConvertiblePreferredStockMembersrt:MaximumMember2026-09-260000862861AIFC:SeriesIConvertiblePreferredStockMembersrt:MinimumMember2026-09-260000862861AIFC:SeriesQConvertiblePreferredStockMember2026-06-282026-09-260000862861AIFC:SeriesQConvertiblePreferredStockMembersrt:MinimumMember2026-09-260000862861AIFC:SeriesQConvertiblePreferredStockMembersrt:MaximumMember2026-09-260000862861AIFC:SeriesIConvertiblePreferredStockMember2026-06-282026-09-260000862861AIFC:SeriesQConvertiblePreferredStockMember2026-09-260000862861AIFC:SeriesQConvertiblePreferredStockMember2025-12-270000862861AIFC:SeriesSConvertiblePreferredStockMemberAIFC:SoinTherapeuticsLLCMember2022-12-280000862861AIFC:SeriesSConvertiblePreferredStockMemberAIFC:SoinTherapeuticsLLCMember2022-12-282022-12-280000862861AIFC:SeriesSConvertiblePreferredStockMemberAIFC:SoinTherapeuticsLLCMembersrt:MinimumMember2022-12-280000862861AIFC:SeriesSConvertiblePreferredStockMemberAIFC:SoinTherapeuticsLLCMembersrt:MaximumMember2022-12-280000862861AIFC:SeriesSConvertiblePreferredStockMember2026-06-282026-09-260000862861AIFC:SeriesSConvertiblePreferredStockMember2026-09-260000862861AIFC:SeriesSConvertiblePreferredStockMember2025-12-270000862861AIFC:SeriesVConvertiblePreferredStockMembersrt:MinimumMember2026-09-260000862861AIFC:SeriesVConvertiblePreferredStockMembersrt:MaximumMember2026-09-260000862861AIFC:SeriesVConvertiblePreferredStockMember2025-12-282026-09-2600008628612023-12-312024-12-280000862861AIFC:SeriesSPreferredStockMember2023-12-312024-12-280000862861AIFC:PrefundedWarrantMember2026-09-260000862861us-gaap:SegmentContinuingOperationsMember2026-06-282026-09-260000862861us-gaap:SegmentContinuingOperationsMember2025-12-282026-09-260000862861us-gaap:SegmentDiscontinuedOperationsMember2026-06-282026-09-260000862861us-gaap:SegmentDiscontinuedOperationsMember2025-12-282026-09-260000862861us-gaap:SegmentContinuingOperationsMember2024-12-292025-09-270000862861us-gaap:SegmentContinuingOperationsMember2025-06-292025-09-270000862861us-gaap:SegmentDiscontinuedOperationsMember2025-06-292025-09-270000862861us-gaap:SegmentDiscontinuedOperationsMember2024-12-292025-09-2700008628612025-12-282026-06-260000862861AIFC:FintechMember2026-06-282026-09-260000862861us-gaap:CorporateAndOtherMember2026-06-282026-09-260000862861AIFC:TotalMember2026-06-282026-09-260000862861AIFC:FintechMember2025-06-292025-09-270000862861us-gaap:CorporateAndOtherMember2025-06-292025-09-270000862861AIFC:TotalMember2025-06-292025-09-270000862861AIFC:FintechMember2025-12-282026-09-260000862861us-gaap:CorporateAndOtherMember2025-12-282026-09-260000862861AIFC:TotalMember2025-12-282026-09-260000862861AIFC:FintechMember2024-12-292025-09-270000862861us-gaap:CorporateAndOtherMember2024-12-292025-09-270000862861AIFC:TotalMember2024-12-292025-09-270000862861AIFC:LiveVenturesIncorporatedMemberus-gaap:RelatedPartyMember2026-06-282026-09-260000862861AIFC:LiveVenturesIncorporatedMemberus-gaap:RelatedPartyMember2025-06-292025-09-270000862861AIFC:LiveVenturesIncorporatedMemberus-gaap:RelatedPartyMember2025-12-282026-09-260000862861AIFC:LiveVenturesIncorporatedMemberus-gaap:RelatedPartyMember2024-12-292025-09-270000862861AIFC:LiveVenturesIncorporatedMemberus-gaap:RelatedPartyMember2026-09-260000862861us-gaap:SubsequentEventMember2026-11-060000862861us-gaap:SubsequentEventMember2026-10-012026-11-060000862861us-gaap:SubsequentEventMember2026-10-312026-10-310000862861us-gaap:SubsequentEventMember2026-10-310000862861us-gaap:SubsequentEventMember2026-11-05iso4217:USDxbrli:sharesiso4217:USDxbrli:sharesAIFC:SegmentAIFC:Integerutr:sqftxbrli:pureiso4217:CAD

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM10-Q

 

☒Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

For the quarterly period ended September 26, 2026

or

☐Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Commission File No. 000-19621

 

AI FINANCIAL CORPORATION

(Exact name of registrant as specified in its charter)

 

Nevada 41-1454591

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

8548 Rozita Lee Ave, Suite 305

Las Vegas, Nevada

 89113
(Address of principal executive offices) (Zip Code)

 

702-997-5968

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, $0.001 par value per share AIFC The Nasdaq Stock Market LLC
    (The Nasdaq Capital Market)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one)

 

Large accelerated filer☐ Accelerated filer☐
Non-accelerated filer☒ Smaller reporting company☒
Emerging growth company☐   

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). ☐ Yes ☒ No

 

As of November 9, 2026, there were 139,836,511 outstanding shares of the registrant’s common stock, with a par value of $0.001.

 

 

 

 
 

 

AI FINANCIAL CORPORATION

 

INDEX TO FORM 10-Q

 

  Page
PART I. FINANCIAL INFORMATION 
   
Item 1.Condensed Consolidated Financial Statements3
   
 Unaudited Condensed Consolidated Balance Sheets as of September 26, 2026 and December 27, 20253
   
 Unaudited Condensed Consolidated Statements of Operations for the 13 and 39 weeks ended September 26, 2026 and September 27, 20254
   
 Unaudited Condensed Consolidated Statements of Cash Flows for the 39 weeks ended September 26, 2026 and September 27, 20255
   
 Unaudited Condensed Consolidated Statements of Stockholders’ Equity for the 13 and 39 weeks ended September 26, 2026 and September 27, 20256
   
 Notes to Unaudited Condensed Consolidated Financial Statements8
   
Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations30
   
Item 3.Quantitative and Qualitative Disclosures About Market Risk35
   
Item 4.Controls and Procedures35
   
PART II. OTHER INFORMATION 
   
Item 1.Legal Proceedings37
   
Item 1A.Risk Factors37
   
Item 2.Unregistered Sales of Equity Securities and Use of Proceeds37
   
Item 3.Defaults Upon Senior Securities37
   
Item 4.Mine Safety Disclosures37
   
Item 5Other Information37
   
Item 6.Exhibits37
   
SIGNATURES38

 

2
 

 

PART I. FINANCIAL INFORMATION

 

ITEM 1. Condensed Consolidated Financial Statements

 

AI FINANCIAL CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(Dollars in thousands, except per-share amounts)

 

  September 26,
2026
  December 27,
2025*
 
  (Unaudited)    
Assets        
Cash $2,558  $2,269 
Short term investment  1,300   — 
Trade and other receivables, net  1,818   2,152 
Digital assets receivable  —   — 
Prepaid expenses and other current assets  1,090   274 
Other current assets  505   381 
Current assets from discontinued operations  —   24,390 
Total current assets  7,271   29,466 
Property and equipment, net  23   28 
Intangible assets, net  18,535   7,282 
Cryptocurrency assets, at fair value  417,441   1,054,663 
Deferred income taxes, net  229,063   83,625 
Goodwill  8,417   8,417 
Notes receivable, net  3,375   — 
Other assets from discontinued operations  14,081   35,974 
Total assets $698,206  $1,219,455 
Liabilities, Mezzanine Equity and Stockholders’ Equity (Deficit)        
Liabilities:        
Accounts payable $2,816  $4,670 
Accrued liabilities - other  3,898   7,689 
Convertible debentures  75   — 
Notes payable  12,507   5,944 
Current liabilities from discontinued operations  1,596   33,096 
Total current liabilities  20,892   51,399 
Notes payable  18,000   8,247 
Other noncurrent liability  1,668   — 
Noncurrent liabilities from discontinued operations  —   607 
Total liabilities  40,560   60,253 
Commitments and contingencies (Note 14)  —   

—

 
Mezzanine equity        
Series S preferred stock — convertible component classified in mezzanine equity (Note 17)  3,856   3,856 
Stockholders’ equity:        
Preferred stock, series A-1 - par value $0.001 per share 2,000,000 authorized, 0 shares issued and outstanding at September 26, 2026 and December 27, 2025  —   — 
Preferred stock, series B - par value $0.001 per share, 34,250 authorized, 34,207 shares issued and outstanding at September 26, 2026 and December 27, 2025  717   717 
Convertible preferred stock, series I - par value $0.001 per share, 2,000,000 authorized, 12,500 and 17,000 shares issued and outstanding at September 26, 2026 and December 27, 2025  —   — 
Preferred stock, series M - par value $0.001 per share, 3,200 authorized, 0 shares issued and outstanding at September 26, 2026 and December 27, 2025  —   — 
Preferred stock, series Q - par value $0.001 per share, 2,000,000 authorized, 867,387 and 925,212 shares issued and outstanding at September 26, 2026 and December 27, 2025  725   725 
Series S preferred stock— permanent equity component (Notes 16 and 17)  7,993   7,993 
Convertible preferred stock, series V - par value $0.001 per share, 125,000 authorized, 0 and 5,000 shares issued and outstanding at September 26, 2026 and December 27, 2025, respectively  —   — 
Preferred stock, value  —   — 
Common stock, $0.001 par; 2,000,000,000 shares authorized; 139,958,768 issued and 139,836,511 outstanding at September 26, 2026; 126,474,169 issued and outstanding at December 27, 2025  140   126 
Treasury stock, at cost, 122,257 and 0 shares at September 26, 2026 and December 27, 2025, respectively  (487)  — 
Accumulated other comprehensive income (loss)  564   (6,306)
Additional paid-in capital  1,562,573   1,551,301 
Accumulated deficit  (921,935)  (402,710)
Equity attributable to AI Financial Corporation shareholders  650,290   1,151,846 
Noncontrolling interest $3,500  $3,500 
Total stockholder’s equity  653,790   1,155,346 
Total liabilities, mezzanine equity and stockholders’ equity $698,206  $1,219,455 

 

* Derived from audited information.

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. Comparative 2025 amounts have been reclassified to present ALT5 Canada and Biotechnology as discontinued operations. Consolidated net income and total earnings per share are unchanged. Amounts may not sum due to rounding.

 

3
 

 

AI FINANCIAL CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME

(UNAUDITED)

(Dollars in thousands, except per-share)

 

  September 26,
2026
  September 27,
2025
  September 26,
2026
  September 27,
2025
 
  For the Thirteen Weeks Ended  For the Thirty-Nine Weeks Ended 
  September 26,
2026
  September 27,
2025
  September 26,
2026
  September 27,
2025
 
Revenues $248  $913  $934  $1,235 
Cost of revenues  160   465   388   789 
Gross profit  88   448   546   446 
Operating expenses:                
Selling, general and administrative expenses  5,524   12,566   10,723   15,090 
Operating loss  (5,436)  (12,118)  (10,177)  (14,644)
Other income (expense):                
Interest income (expense), net  (469)  (359)  (1,000)  (858)
Unrealized gain on exchange transactions  —   234   —   234 
Unrealized loss on crypto-currency assets  (3,841)  72,836   (637,222)  72,836 
Realized gain (loss) on exchange transactions  83   —   194   — 
Other income (expense), net  (3,204)  2   (1,552)  (78)
Total other (expense) income, net  (7,431)  72,713   (639,580)  72,134 
Loss before benefit (provision) for income taxes  (12,867)  60,595   (649,757)  57,490 
Income tax benefit (provision)  4,234   (13,287)  146,352   (15,922)
Net income (loss) from continuing operations  (8,633)  47,308   (503,405)  41,568 
Loss from discontinued operations  (8,943)  (3,910)  (15,326)  (9,972)
Income tax benefit (provision) from discontinued operations  (599)  5,564   (494)  5,390 
Net income (loss) from discontinued operations  (9,542)  1,654   (15,820)  (4,582)
Net income (loss) $(18,175) $48,962  $(519,225) $36,986 
Other comprehensive income:                
Foreign currency translation and related reclassification adjustments  

1,818

   

2,236

   

6,870

   

7,521

 
Comprehensive income (loss)  

(16,357

)  

51,198

   

(512,355

)  

44,507

 

Net income (loss) per share:

                
Net income (loss) per share from continuing operations, basic $(0.06) $0.65  $(3.74) $1.17 
Net income (loss) per share from continuing operations, diluted $(0.06) $0.28  $(3.74) $0.31 
Net income (loss) per share from discontinued operations, basic $(0.07) $0.02  $(0.12) $(0.13)
Net income (loss) per share from discontinued operations, diluted $(0.07) $0.01  $(0.12) $(0.03)
Net income (loss) per share, basic $(0.13) $0.67  $(3.86) $1.04 
Net income (loss) per share, diluted $(0.13) $0.29  $(3.86) $0.28 
Weighted average common shares outstanding:                
Basic  139,836,511   72,887,313   134,429,846   35,662,862 
Diluted  139,836,511   168,657,684   134,429,846   132,041,354 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

4
 

 

AI FINANCIAL CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

(In thousands)

 

  September 26, 2026  September 27, 2025 
  For the Thirty-Nine Weeks Ended 
  September 26, 2026  September 27, 2025 
OPERATING ACTIVITIES:        
Net income (loss) from continuing operations $(503,405) $41,568 
Adjustments to reconcile net loss to net cash provided by operating activities:        
Depreciation and amortization  480   2,456 
Stock-based compensation  —   5,901 
Amortization and other noncash debt adjustments  950   225 
Amortization of right-of-use assets  —   46 
Unrealized gain/loss on cryptocurrency assets  637,222   (72,836)
Digital asset transaction adjustments  (194)  184 
Realized gain on digital assets  —   3,591 
Change in deferred income taxes  (145,438)  11,834 
Other  (2,955)  (2,741)
Changes in assets and liabilities:        
Accounts receivable  334  2,541 
Digital assets receivable  —   (3,973)
Prepaid expenses and other current assets  (804)  (4,033)
Accounts payable and accrued expenses  (6,389)  4,197 
Digital assets payable  —   (4,427)
Operating cash flows from discontinued operations  (806)  — 
Net cash used in operating activities  

(21,005

)  (15,467)
INVESTING ACTIVITIES:        
Purchases of short-term certificates of deposit  (5,000)  — 
Proceeds from redemption of certificates of deposit  3,700   — 
Purchases of property and equipment  —   (16)
Cash acquired in Mswipe acquisition  —   122 
Cryptocurrency assets purchased  —   (716,717)
Cryptocurrency assets redeemed  —   5,309 
Cash disposed of with ALT5 Canada  (1,024)  — 
Net cash (used in) provided by investing activities  

(2,324

)  (711,302)
FINANCING ACTIVITIES:        
Proceeds from equity financing  —   750,000 
Payments of placement fees  —   (32,476)
Purchase of treasury common shares  (487)  — 
Proceeds from the issuance of notes payable  18,000   4,032 
Payments on notes payable  (765)  (2,131)
Payments on related party notes payable  —   (36)
Financing cash flows from discontinued operations  —  — 
Net cash provided by financing activities  16,748   719,389 
Effect of changes in exchange rate on cash and cash equivalents  6,870   7,521 
(DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS  289   141 
CASH AND CASH EQUIVALENTS, beginning of period  2,269   7,177 
LESS CASH OF DISCONTINUED OPERATIONS, end of period  —   — 
CASH AND CASH EQUIVALENTS, end of period $2,558  $7,318 
Supplemental cash flow disclosures:        
Cash paid for interest (continuing and discontinued) $1,496  $— 
Noncash financing and investing activities:        
Common stock issued for Block Street asset acquisition $11,729  $— 
Common stock issued for prefunded warrants granted $—  $750,000 
Notes payable converted to common stock $—  $2,200 
Common stock issued for the acquisition of Mswipe $—  $5,184 
Common stock warrants issued for the acquisition of Mswipe $—  $1,652 
Drew common stock issued for the acquisition of Mswipe $—  $1,668 
Convertible Preferred Series Q shares converted to common stock $—  $500 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

5
 

 

AI FINANCIAL CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

(UNAUDITED)

(Dollars in thousands)

 

  Series A-1 Shares  Series A-1 Amount  Series S-1 Shares  Series S-1 Amount  Series B Shares  Series B Amount  Series I Shares  Series I Amount  

Series M

Shares

  

Series M

Amount

  Series Q Shares  Series Q Amount  

Series V

Shares

  Series V Amount  Common Stock Shares  Common Stock Amount  Additional Paid-in Capital  Treasury Stock  Accumulated Deficit  Accumulated Other Comprehensive Income  Noncontrolling Interest  Total Stockholders Equity 
  Series A-1 Shares  Series A-1 Amount  Series S-1 Shares  Series S-1 Amount  Series B Shares  Series B Amount  Series I Shares  Series I Amount  

Series M

Shares

  

Series M

Amount

  Series Q Shares  Series Q Amount  

Series V

Shares

  Series V Amount  Common Stock Shares  Common Stock Amount  Additional Paid-in Capital  Treasury Stock  Accumulated Deficit  Accumulated Other Comprehensive Income  Noncontrolling Interest  

Total Stockholders’

Equity

 
Balance, December 27, 2025  —   —   100,000   7,993   34,207   717   17,000   —   —   —   925,212   725   —   —   126,474,169   126   1,551,301   —   (402,710)  (6,306)  3,500   1,155,346 
Common stock issued for Series Q convertible stock converted  —   —   —   —   —   —   —   —   —   —   (57,825)  —   —   —   57,825   1   —   —   —   —   —   1 
Common stock issued for Series I convertible stock converted  —   —   —   —   —   —   (4,500)  —   —   —   —   —   —   —   450,000   6   —   —   —   —   —   6 
Common stock issued for consulting agreement  —   —   —   —   —   —   —   —   —   —   —   —   —   —   6,000   —   12   —   —   —   —   12 
Common stock issued for Debenture converted  —   —   —   —   —   —   —   —   —   —   —   —   —   —   160,562   2   1,186   —   —   —   —   1,188 
Common stock issued in lieu of notes payable obligation  —   —   —   —   —   —   —   —   —   —   —   —   —   —   17,698   —   26   —   —   —   —   26 
Foreign currency adjustment  —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   8,077   —   8,077 
Prior period adjustment  —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   (9)  9   —   88   —   —   88 
Net loss  —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   (271,493)  —   —   (271,493)
Balance, March 28, 2026  —   —   100,000   7,993   34,207   717   12,500   —   —   —   867,387   725   —   —   127,166,254   126   1,552,534   —   (674,115)  1,771   3,500   893,251 
Treasury share buyback  —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   (487)  —   —   —   (487)
ALT5 Sigma Corp common stock issued for Block Street  —   —   —   —   —   —   —   —   —   —   —   —   —   —   12,670,257   13   11,707   —   —   —   —   11,729 
Foreign currency adjustment  —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   (3,025)  —   (3,025)
Net loss  —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   (229,557)  —   —   (229,557)
Balance, June 27, 2026  —   —   100,000   7,993   34,207   717   12,500   —   —   —   867,387   725   —   —   139,836,511   139   1,564,241   (487)  (903,672)  (1,254)  3,500   671,902 
Consolidation and other equity adjustments  —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   1   (1,668)  —   —   —   —   (1,667)
Foreign currency and noncompete basis adjustments  —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   1,818   —   1,818 
Reversal of prior-period presentation adjustment  —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   (88)  —   —   (88)
Net loss  —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   (18,175)  —   —   (18,175)
Balance, September 26, 2026  —   —   100,000   7,993   34,207   717   12,500   —   —   —   867,387   725   —   —   139,836,511   140   1,562,573   (487)  (921,935)  564   3,500   653,790 

 

6
 

 

  Series A-1 Shares  Series A-1 Amount  Series S-1 Shares  Series S-1 Amount  Series B Shares  Series B Amount  Series I Shares  Series I Amount  

Series M

Shares

  

Series M

Amount

  Series Q Shares  Series Q Amount  Series V Shares  Series V Amount  Common Stock Shares  Common Stock Amount  Additional Paid-in Capital  Accumulated Deficit  Accumulated Other Comprehensive Income  Noncontrolling Interest  Total Stockholders Equity 
  Series A-1 Shares  Series A-1 Amount  Series S-1 Shares  Series S-1 Amount  Series B Shares  Series B Amount  Series I Shares  Series I Amount  

Series M

Shares

  

Series M

Amount

  Series Q Shares  Series Q Amount  Series V Shares  Series V Amount  Common Stock Shares  Common Stock Amount  Additional Paid-in Capital  Accumulated Deficit  Accumulated Other Comprehensive Income  Noncontrolling Interest  

Total Stockholders’

Equity

 
Balance, December 28, 2024  23,480   —   100,000   7,993   34,207   8,552   17,000   —   3,200   —   925,212   1,321   5,000   —   15,417,693   9   62,207   (56,879)  (2,317)  3,925   24,811 
Common stock issued for consulting agreement  —   —   —   —   —   —   —   —   —   —   —   —   —   —   15,499   —   94   —   —   —   94 
Common stock issued for warrants exercised  —   —   —   —   —   —   —   —   —   —   —   —   —   —   45,455   —   78   —   —   —   78 
Common stock issued for Series V convertible stock converted  —   —   —   —   —   —   —   —   —   —   —   —   (5,000)  —   600,000   —   —   —   —   —   — 
Foreign currency adjustment  —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   3,633   —   3,633 
Net loss  —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   (2,861)  —   (425)  (3,286)
Balance, March 29, 2025  23,480   —   100,000   7,993   34,207   8,552   17,000   —   3,200   —   925,212   1,321   —   —   16,078,647   9   62,379   (59,740)  1,316   3,500   25,330 
Series A-1 adjustment  20,770   —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   — 
Conversion of Series A-1 Preferred  (44,250)  —   —   —   —   —   —   —   —   —   —   —   —   —   885,000   —   —   —   —   —   — 
ALT5 Sigma Corp common stock issued for RSU’s granted  —   —   —   —   —   —   —   —   —   —   —   —   —   —   800,000   1   605   —   —   —   606 
ALT5 Sigma Corp common stock issued for note payable obligations  —   —   —   —   —   —   —   —   —   —   —   —   —   —   1,182,013   1   721   —   —   —   722 
ALT5 Sigma Corp common stock issued for consulting agreement  —   —   —   —   —   —   —   —   —   —   —   —   —   —   300,000   —   1,687   —   —   —   1,687 
ALT5 Sigma Corp common stock issued for Mswipe acquisition  —   —   —   —   —   —   —   —   —   —   —   —   —   —   1,000,000   —   5,184   —   —   —   5,184 
ALT5 Sigma Corp common stock warrants for Mswipe acquisition  —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   1,652   —   —   —   1,652 
Alyea common stock warrants for Mswipe acquisition  —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   1,668   —   —   —   1,668 
Common stock issued for Series Q convertible stock converted  —   —   —   —   —   —   —   —   —   —   (192,752)  (500)  —   —   192,752   —   500   —   —   —   — 
ALT5 Sigma Corp common stock issued for professional services  —   —   —   —   —   —   —   —   —   —   —   —   —   —   17,511   —   165   —   —   —   165 
Foreign currency adjustment  —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   1,652   —   1,652 
Net loss  —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   (9,115)  —   (300)  (9,415)
Balance, June 28, 2025  —   —   100,000   7,993   34,207   8,552   17,000   —   3,200   —   732,460   821   —   —   20,455,923   11   74,561   (68,855)  2,968   3,200   29,251 
Balance  —   —   100,000   7,993   34,207   8,552   17,000   —   3,200   —   732,460   821   —   —   20,455,923   11   74,561   (68,855)  2,968   3,200   29,251 
Common stock issued for Series M conversion  —   —   —   —   —   —   —   —   (3,200)  —   —   —   —   —   90,000   —   —   —   —   —   — 
Common stock issued for equity raise  —   —   —   —   —   —   —   —   —   —   —   —   —   —   100,330,000   100   751,144   —   —   —   751,244 
Common stock issued for RSU’s granted  —   —   —   —   —   —   —   —   —   —   —   —   —   —   555,000   1   5,295   —   —   —   5,296 
Common stock issued for prefunded warrants  —   —   —   —   —   —   —   —   —   —   —   —   —   —   1,000,000   1   749,999   —   —   —   750,000 
Common stock for warrants exercised  —   —   —   —   —   —   —   —   —   —   —   —   —   —   1,229,551   2   155   —   —   —   157 
Common stock issued for notes payable obligations  —   —   —   —   —   —   —   —   —   —   —   —   —   —   2,429,155   2   1,479   —   —   —   1,481 
Payment of placement fees for equity raise  —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   (32,545)  —   —   —   (32,545)
Net income and foreign currency adjustment  —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   —   48,962   2,236   —   51,198 
Balance, September 27, 2025  —   —   100,000   7,993   34,207   8,552   17,000   —   —   —   732,460   821   —   —   126,089,629   117   1,550,088   (19,893)  5,204   3,200   1,556,082 
Balance  —   —   100,000   7,993   34,207   8,552   17,000   —   —   —   732,460   821   —   —   126,089,629   117   1,550,088   (19,893)  5,204   3,200   1,556,082 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

7
 

 

Note 1: Background

 

The accompanying consolidated financial statements include the accounts of AI Financial Corporation, a Nevada corporation, and its subsidiaries (collectively, the “Company” or “AIFC”). Effective April 28, 2026, the Company changed its name to “AI Financial Corporation” from “Alt5 Sigma Corporation”. The Company also changed its Nasdaq common stock symbol to “AIFC” from “ALTS.” Previously, effective July 15, 2024, the Company had changed its corporate name to “ALT5 Sigma Corporation” from “JanOne Inc.” and also changed its Nasdaq common stock ticker symbol to “ALTS” from “JAN”. In each instance, the corporate name changes were effected through a parent/subsidiary short-form merger of Company’s wholly-owned Nevada subsidiary formed solely for the purpose of effectuating the name change, whereby that “name change subsidiary” subsidiary merged with and into the Company, with the Company being the surviving entity, albeit with its new name.

 

The Company had threeoperating segments – Fintech, Biotechnology, and Corporate and Other. We have previously announced our intention to capitalize Drew Therapeutics Corporation (“Drew”), formerly Alyea Therapeutics Corporation, as a subsidiary with certain of our biotechnology assets, acquire an additional biotechnology asset, and then engage in a financing of that subsidiary. In connection with that potential series of transactions, the accounts for the Biotechnology segment have been presented as discontinued operations in the accompanying consolidated financial statements.

 

On July 29, 2026, the Company agreed to sell ALT5 Sigma Canada, Inc. (“ALT5 Canada”), an indirect wholly owned subsidiary. The transaction closed on August 3, 2026. The results of ALT5 Canada are presented within discontinued operations in the accompanying consolidated financial statements.

 

Fintech

 

On May 15, 2024, the Company acquired ALT5 Sigma, Inc. (“ALT5 Subsidiary”). ALT5 Subsidiary is a fintech company that provides next generation blockchain-powered technologies to enable a migration to a new global financial paradigm. ALT5 Subsidiary, through its respective subsidiaries, offers two main platforms to its customers: “ALT5 Pay” and “ALT5 Prime.” ALT5 Pay is a crypto-currency payment gateway that enables registered and approved global merchants to accept and make crypto-currency payments or to integrate the ALT5 Pay payment platform into their application or operations using the plugin with WooCommerce and/or ALT5 Pay’s checkout widgets and APIs. Merchants have the option to convert to fiat currency (US Dollars, Canadian Dollars, Euros, and British Pounds Sterling) automatically or to receive their payment in digital assets (see Note 3). The principal subsidiary of the Alt 5 Subsidiary, ALT5 Canada, was sold on August 3, 2026 (see Note 4).

 

On May 9, 2025, the Company acquired Fortress II Holdings Ltd. d/b/a Mswipe. Mswipe is a next-generation payment solutions provider offering multi-currency, fiat payment card services, along with crypto-enabled capabilities through its existing integration with the ALT5 Subsidiary platform. Its suite of physical and virtual cards, available on both the Visa® and Mastercard® networks, allows users to seamlessly spend traditional and digital currencies worldwide (see Note 3).

 

Biotechnology

 

During September 2019, the Company, through its biotechnology segment, broadened its business perspectives to become a pharmaceutical company focused on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. Effective December 28, 2022, the Company acquired Soin Therapeutics LLC, a Delaware limited liability company (“STLLC”), and its product, a patent-pending, novel formulation of low-dose naltrexone (“JAN123”). The product is being developed for the treatment of Complex Regional Pain Syndrome (CRPS), an indication that causes severe, chronic pain generally affecting the arms or legs. At present, there are no truly effective treatments for CRPS. Because of the relatively small number of patients afflicted with CRPS, the FDA has granted Orphan Drug Designation for any product approved for treatment of CRPS. This designation will provide the Company with tax credits for its clinical trials, exemption of user fees, and the potential of seven years of market exclusivity following approval. In addition, development of orphan drugs currently also involves smaller trials and quicker times to approval, given the limited number of patients available to study. However, there can be no assurance that the product will receive FDA approval or that it will result in material sales. In that regard, we have previously announced our intention to capitalize a subsidiary with certain of our biotechnology assets, acquire an additional biotechnology asset, and then engage in a financing of that subsidiary. The short-term intended result of that series of transactions would be for us to own a controlling interest in that subsidiary, but to decouple it from us so that it would operate on a stand-alone basis. In connection with the Company’s prospective spinoff of Drew, accounts for the Biotechnology segment have been presented as discontinued operations in the accompanying consolidated financial statements (see Note 4).

 

Corporate and Other

 

Our Corporate and Other segment consists of WLFI assets, including any additions, redemptions, or mark-to-market changes in value, which are recorded within the Company’s Corporate and Other segment.

 

8
 

 

The WLFI treasury program was initiated on August 12, 2025, with purchases executed in two tranches at $0.20 per token:

 

 1.Tranche 1: 3,750,000,000 WLFI tokens
   
 2.Tranche 2: 3,584,000,000WLFI tokens (adjusted slightly from initial 3,750,000,000 to reflect final settlement after expenses from the proceeds of the financing completed in August 2025.

 

The original WLFI purchase agreements imposed contractual transfer restrictions on 3,533,585,650 tokens acquired under the Token Purchase Agreement and 3,750,000,000 tokens acquired under the Securities Purchase Agreement. The agreements included twelve-month restriction periods, permitted collateral, staking or lending uses in specified circumstances, and additional stockholder-approval, charter-amendment and resale-registration conditions for release of the second tranche. The passage of a restriction period does not by itself establish that all release conditions have been met.

 

In connection with the WLFI treasury program, the Company entered into lock-up agreements restricting certain equity issuances. Pursuant to the Purchase Agreements, the Company agreed not to issue, or enter into any agreement to issue, shares of Common Stock or Common Stock equivalents, or file any registration statement or amendment thereto, for a period of 30 days following the closing date of the Offerings, subject to customary exceptions including issuances under the ATM Sales Agreement.

 

In addition, each of the Company’s directors and executive officers is subject to a lock-up agreement prohibiting the sale, pledge, or other transfer or disposition of 50% of their shares of Common Stock, or securities convertible into or exchangeable for Common Stock, for a period of 90 days following the closing date, with the remaining 50% subject to the same restrictions until the later of 90 days following the closing date or the date Stockholder Approval was obtained. Transfers for bona fide estate or tax planning purposes are permitted, provided the transferee agrees to be bound by the same lock-up terms.

 

WLFI is considered a related party to the Company by virtue of the following relationships. Zachary Witkoff, the Chairman of the Company’s Board of Directors, is a Co-Founder and Chief Executive Officer of WLFI. Zachary Folkman, a member of the Company’s Board of Directors, is also a Co-Founder of WLFI. In addition, WLFI is the record owner of 1,000,000 shares of the Company’s Common Stock and has contractual rights to pre-funded warrants to purchase up to 99,000,000 additional shares of Common Stock, as well as warrants to purchase up to 20,000,000shares of Common Stock at exercise prices ranging from $7.50 to $9.75 per share, each acquired in connection with the WLFI treasury program. As a result of these relationships, WLFI is deemed a related party under ASC 850, Related Party Disclosures, and all transactions between the Company and WLFI, including the Token Purchase Agreements pursuant to which the Company acquired its WLFI token holdings and the Master Loan and Security Agreement entered into in January 2026, have been reviewed and approved by the Audit Committee of the Board of Directors in accordance with the Company’s related party transaction policy

 

All acquisitions of WLFI tokens were executed through on-chain transactions and direct Token Purchase Agreements with the WLFI Foundation. The Company did not hold any WLFI tokens prior to August 12, 2025.

 

Our Corporate and Other segment consists of certain corporate general and administrative costs.

 

The Company reports on a 52- or 53-week fiscal year. The Company’s 2025 fiscal year (“2025”) ended on December 27, 2025, and the current fiscal year (“2026”) will end on December 26, 2026.

 

Liquidity Considerations

 

The Company incurred a net loss from continuing operations of approximately $503.4 million and a consolidated net loss of approximately $519.2million for the thirty-nine weeks ended September 26, 2026. Current assets of approximately $7.3 million and current liabilities of approximately $20.9 million result in a working-capital deficit of approximately $13.6 million. These conditions raise substantial liquidity concerns.

 

The Company holds 7,283,585,650 WLFI tokens. The liquidity available from those holdings depends on contractual transfer, collateral and release conditions and the ability to monetize the tokens. Their quoted fair value is not equivalent to unrestricted cash available to fund operations.

 

The Company’s ability to fund operations and satisfy obligations depends on operating cash flows, available financing and the realization of assets, including WLFI holdings subject to applicable contractual conditions.

 

Note 2: Summary of Significant Accounting Policies

 

Basis of Presentation

 

The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the U.S. (“U.S. GAAP”) and with the instructions to Form 10-Q and Article 10 of Regulation S-X for interim financial information. Accordingly, these financial statements do not include all of the information and notes required for complete financial statements prepared in conformity with U.S. GAAP. In our opinion, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. However, the Company’s results of operations for the interim periods presented are not necessarily indicative of the results that may be expected for the full year. For further information, refer to the consolidated financial statements and notes thereto included in our Form 10-K for the fiscal year ended December 27, 2025.

 

9
 

 

Principles of Consolidation

 

The accompanying consolidated financial statements include the accounts of the Company and its subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.

 

Financial Statement Reclassification

 

Certain prior-period amounts have been reclassified to conform to the current period presentation. These reclassifications relate primarily to the presentation of the Biotechnology segment and ALT5 Canada as discontinued operations.

 

Use of Estimates

 

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumption that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Significant estimates made in connection with the accompanying consolidated financial statements include the fair value in connection with the Series S convertible preferred stock issued in the December 28, 2022 acquisition of STLLC, valuation allowance against deferred tax assets, and estimated useful lives for intangible assets.

 

Financial Instruments

 

Financial instruments consist primarily of cash, trade and other receivables, and obligations under accounts payable, accrued expenses and notes payable. The carrying amounts of trade and other receivables, accounts payable, accrued expenses and short-term notes payable approximate fair value because of the short maturity of these instruments. The fair value of the long-term debt is calculated based on interest rates available for debt with terms and maturities similar to the Company’s existing debt arrangements, unless quoted market prices were available (Level 2 inputs). The carrying amounts of long-term debt at September 26, 2026 and December 27, 2025 approximate fair value.

 

Cryptocurrency Assets

 

The Company’s cryptocurrency assets consist of World Liberty Financial (“WLFI”) tokens, a scarce, governance-enabled digital asset with long-term capital preservation and appreciation potential, inflation-hedging characteristics, and embedded productivity through protocol participation and revenue-sharing mechanisms. With a fixed maximum supply of 100billion tokens, WLFI powers decentralized lending, borrowing, staking, and governance within a rapidly growing DeFi platform.

 

Cryptocurrency assets acquired are initially recorded at cost, which represents the cash, cash equivalents, or other financial assets paid to acquire the asset, including transaction fees. Cryptocurrency assets are subsequently measured in accordance with ASC 350-60, Intangibles—Goodwill and Other—Accounting for and Disclosure of Cryptocurrency Assets, at fair value in the statement of financial position with unrealized gains and losses resulting from changes in fair value recognized in net income. The Company determines and records at each reporting period the fair value of its cryptocurrency assets in accordance with ASC 820, Fair Value Measurement, based on quoted (unadjusted) prices. Changes in the fair value are recognized in net income within “Unrealized gain on crypto assets”, while realized gains and losses from the derecognition of crypto assets are included in “Realized gain on crypto assets, net” in the Company’s condensed consolidated statements of operations. Purchases and redemptions of cryptocurrency assets are reflected as cash flows from investing activities in the consolidated statements of cash flows.

 

Digital Assets and other Receivables

 

Digital assets and other receivables are the Company’s digital assets and its customer prepayments in the form of digital assets. The Company held all digital assets in secure non-custodial wallets through the wallet services from Fireblocks and Utila. As of September 26, 2026, and December 27, 2025, the outstanding balances of digital assets and other receivables was niland approximately $18.0million, respectively.

 

Digital Assets and other Payables

 

Digital assets and other payables are liabilities that represent the Company’s obligation to deliver the settlement of transactions in the form of digital assets and or cash. The Company safeguards these digital assets and/or cash for customers and is obligated to safeguard them from loss, theft, or other misuse. The Company recognizes digital assets and other payables, on initial recognition and at each reporting date, at fair value of the digital assets. Any loss, theft, or other misuse would impact the measurement of digital assets and other payables. As of September 26, 2026, the outstanding balance of digital assets and other payables was nil. As of December 27, 2025, the outstanding balance of digital assets and other payables was approximately $28.7 million, of which approximately $18.0 million were digital assets and $4.0 million were cash deposits.

 

10
 

 

Revenue Recognition

 

Revenue recognition applies to the Company’s Fintech segment only, as the Company’s Biotech segment has not recognized revenue to date. Revenue is recognized under Topic 606 in a manner that reasonably reflects the delivery of its services and products to customers in return for expected consideration and includes the following elements:

 

 1.Executed contracts with the Company’s customers that it believes are legally enforceable;

 

 2.Identification of performance obligations in the respective contract;

 

 3.Determination of the transaction price for each performance obligation in the respective contract;

 

 4.Allocation of the transaction price to each performance obligation; and

 

 5.Recognition of revenue only when the Company satisfies each performance obligation.

 

These five elements, as applied to each of the Company’s revenue category, are summarized below:

 

 1.Product sales – revenue is recognized at the time of sale of equipment to the customer.

 

 2.Service sales – revenue is recognized based on when the service has been provided to the customer.

 

The Company’s service is comprised of a single performance obligation to buy and sell or convert digital assets to currencies. That is, the Company is the counter-party to all transactions between customers and liquidity providers and presents revenue for the fees earned on a net basis.

 

The Company is acting as principal in all transactions, and control the digital assets being provided before it is transferred to the buyer, and has risk related to the digital assets, and is responsible for the fulfillment of the digital asset transactions. The Company sets the price for the digital assets by aggregating prices from several liquidity providers and displays them on the Company’s platform. As a result, the Company acts as a price discovery service and acts as a principal facilitating the ability for a customer to purchase or sell digital assets.

 

The Company considers its performance obligation satisfied, and recognizes revenue, at the point in time that the transaction is processed. Contracts with customers are usually open-ended and can be terminated by either party without a termination penalty. Therefore, contracts are defined at the transaction level and do not extend beyond the service already provided.

 

The Company charges a fee at the transaction level. The transaction price, represented by the trading fee, is calculated based on volume and varies depending on payment type and the value of the transaction. Digital asset purchases or sale transactions executed by a customer on the Company’s platform is based on tiered pricing that is driven primarily by transaction volume processed for a specific historical period. The Company has concluded that this volume-based pricing approach does not constitute a future material right since the discount is within a range typically offered to a class of customers with similar volume. The transaction fee is collected from the customer at the time the transaction is executed. In certain instances, the transaction fee can be collected in digital assets, with revenue measured based on the amount of digital assets received and the fair value of the digital assets at the time of the transaction. The Company also marks up or down the digital asset prices and earns revenue from the spread between the buying and selling price. The Company also earns a fee from transfers of currencies and or digital assets. The transfer fees are nominal and are set to offset the fees associated with banking and/or blockchain mining fees.

 

The Company receives consideration in the form of digital assets as payment for commissions and other fees and utilizes these assets as part of its working capital. In accordance with ASC 606, the fair value of digital assets received is measured based on quoted prices in active markets on the date control of the related goods or services transfers to the customer. Subsequent to initial recognition, the Company measures digital assets at fair value using quoted prices obtained from active, highly liquid exchanges that the Company has determined to be its principal market. Because these valuations are based on unadjusted quoted prices for identical assets in active markets, the fair value measurements are classified within Level 1 of the fair value hierarchy. The Company presents these assets within other current assets on its consolidated balance sheets.

 

11
 

 

Stock-Based Compensation

 

The Company from time to time grants restricted stock units, warrants, and stock options to employees, non-employees, and Company executives and directors. Such awards are valued based on the grant date fair-value of the instruments. The value of each award is amortized on a straight-line basis over the vesting period.

 

Recently Issued Accounting Pronouncements

 

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”). ASU 2023-09 requires enhanced annual disclosures regarding the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, and may be adopted on a prospective or retrospective basis. The Company adopted this pronouncement effective with its fiscal year ending December 27, 2025.

 

Note 3: Mergers and Acquisitions

 

Block Street

 

On April 20, 2026, the Company entered into, a Stock Exchange Agreement (the “SEA”) with the four Stockholders’ of Block Street Corp., a Nevada corporation (“Block Street”), pursuant to which the Company acquired 100% of the issued and outstanding equity interests of Block Street in a share-for-share exchange, and Block Street became a wholly-owned subsidiary of the Company. Block Street operates a platform designed to support token issuances aligned with applicable regulatory frameworks and the tokenization of real-world assets. Block Street’s capabilities have not yet been deployed commercially and Block Street has not generated revenues to date.

 

The Company evaluated the acquired set under ASC 805 and concluded that it did not meet the definition of a business. Accordingly, the transaction was accounted for as an asset acquisition under ASC 805-50 rather than as a business combination.

 

The purchase price for this transaction consisted of 12,670,257 shares of the Company’s common stock issued at closing, valued at approximately $12.0 million. We also granted the sellers the right to two earn-out payments in the amount of the first earnout of $15.0 million (payable in 5five (5)-year pre-funded warrants exercisable for up to 15,837,821 shares of common stock with an initial aggregate exercise price of $15.0 million) at the point in time if, or when, Block Street generates US GAAP-compliant net revenues, applied consistently with the Company’s historical accounting policies, of not less than $20.0 million on a trailing four-quarter reporting basis. The second earnout of approximately $16.0 million payable in 5five (5)-year pre-funded warrants exercisable for up to 16,893,675 shares of common stock with an initial aggregate exercise price of $16.0 million) at the point in time if, or when, Block Street generates US GAAP-compliant Modified Operating Income, defined in the SEA as Net Operating Income plus realized gains minus realized losses from token sale operations, of not less than $8.0 million on a trailing four-quarter reporting basis.

 

The fair value of the purchase price components outlined above was $11.7 million due to fair value adjustments for the contingent consideration, cash acquired, and working capital adjustments, as detailed below (in $000’s):

 Schedule of Business Acquisition

     
ALT5 Common stock $11,729 
Total purchase price $11,729 

 

The table below outlines the purchase price allocation of the purchase for Block Street to the acquired identifiable intangible assets (in $000’s):

Schedule of Business Acquisition 

 

     
Total purchase price $11,729 
Total intangible assets acquired $11,729 

 

Mswipe

 

Effective on May 9, 2025, the Company and our indirect, wholly-owned second-tier Canadian subsidiary entered into an agreement to purchase all of the outstanding capital stock of Fortress II Holdings Ltd. d/b/a Mswipe, an entity that, through its subsidiaries, offers multi-currency, fiat- and crypto-enabled payment card services of Mswipe. The company conducts business under the name Mswipe. Through a suite of physical and virtual cards that are available on both the Visa® and Mastercard® networks, the acquired operations enable users to seamlessly spend traditional and digital currencies across the globe. The platform is built with robust compliance frameworks, advanced security protocols, and real-time exchange capabilities, which allow for fast, secure, and borderless transactions. This is a B2B solution, which, when combined with our other product offerings, bridges the gap between the crypto economy and traditional financial systems—while ensuring regulatory alignment, interoperability with existing payment networks, and a seamless user experience for institutional partners and their end-users.

 

12
 

 

The purchase price for this transaction consisted of our (i) issuing onemillion restricted shares of our common stock to the threesellers, valued at the Historical NOCP on May 9, 2025 of $6.10, (ii) granting five hundred thousand (500,000) 4four (4)-year common stock warrants to the threesellers, with a per-share exercise price of $5.50(which was the approximate market price at the time that we reached an agreement in principal for this transaction), (iii) issuing shares in Drew to twoof the sellers of Mswipe, which shares we then valued at $4.8million, and (iv) issuing two 14-month straight promissory notes in the aggregate initial principal balance of approximately one million dollars with an interest rate at the AFR for quarterly compounded notes of 3.99% per annum and all principal and interest due at the maturity date. We also are acknowledging an equivalent 14-month term straight promissory note at the acquired company level that pre-dated our acquisition. The principal balance of this note, as of May 9, 2025, was approximately $5.1million and the interest was reset to match that of the twonotes that we issued. We also granted the sellers the right to oneearn-out payment in the amount of $20.0million (payable in cash or unregistered shares of our common stock) at the point in time if, or when, Mswipe generates a minimum of $15.0million in annualized or actual total revenue from Mswipe’s operations.

 

The fair value of the purchase price components outlined above was $14.2 million due to fair value adjustments for the contingent consideration, cash acquired, and working capital adjustments, as detailed below (in $000’s):

 Schedule of Business Acquisition

     
ALT5 Common stock $5,185 
Common stock warrants  1,652 
Seller notes  5,695 
Drew Common Stock  1,668 
Total purchase price $14,200 

 

Under the preliminary purchase price allocation, the Company recognized goodwill of approximately $8.4 million, which is calculated as the excess of both the consideration exchanged and liabilities assumed as compared to the fair value of the identifiable assets acquired. The values assigned to the assets acquired and liabilities assumed are based on their estimates of fair value available as of May 9, 2025, as calculated by an independent third-party firm. Because the transaction was considered a stock purchase for tax purposes, none of the goodwill arising from the acquisition will deductible for tax purposes. The table below outlines the purchase price allocation of the purchase for Mswipe to the acquired identifiable assets, liabilities assumed and goodwill (in $000’s):

Schedule of Assets Liabilities Assumed Goodwill 

     
Total purchase price $14,200 
Accounts payable  1,400 
Deferred taxes  2,038 
Total liabilities assumed  3,438 
Total consideration  17,638 
Cash  122 
Accounts receivable  1,218 
Property and equipment  20 
Intangible assets    
Customer relationships  6,525 
Trade names  500 
Developed technology  675 
Subtotal intangible assets  7,700 
Other  162 
Total assets acquired  9,222 
Total goodwill  8,416 

 

Proforma Information

 

The table below presents selected proforma information for the Company for the 13 and 39 weeks ended September 27, 2025, assuming that the acquisition had occurred on December 31, 2023 (the beginning of the Company’s 2024 fiscal year), pursuant to ASC 805-10-50. This proforma information does not purport to represent what the actual results of operations of the Company would have been had the acquisition occurred on that date, nor does it purport to predict the results of operations for future periods (in $000’s).

Schedule of Proforma Information  

             
  As Reported  Adjustments  Proforma 
  

AI Financial

Corporation

Unaudited 13

weeks ended

September 27, 2025

  

Mswipe

Unaudited 13

weeks ended

September 27, 2025

  Adjustments(1)  

AI Financial

Corporation for

the 13 weeks

ended

September 27, 2025

 
Net revenue $7,575  $913      $8,438 
Net income $48,962  $2,213  $(89) $51,086 
Earnings per basic common share $0.67          $0.70 
Earnings per basic diluted share $0.29          $0.30 

 

13
 

 

             
  As Reported  Adjustments  Proforma 
  

AI Financial

Corporation

Unaudited 39

weeks ended

September 27, 2025

  

Mswipe

Unaudited 39

weeks ended

September 27, 2025

  Adjustments(1)  

AI Financial

Corporation for

the 39 weeks

ended

September 27, 2025

 
Net revenue $19,467  $1,235      $20,702 
Net income $36,986  $(789) $(266) $35,931 
Earnings per basic common share $1.04          $1.01 
Earnings per basic diluted share $0.28          $0.27 

 

(1)Adjustments are related to adjustments made for the following:

 

● Amortization expense of definite-lived intangible assets has been adjusted based on the preliminary fair value at the acquisition date.

 

Note 4: Discontinued Operations

 

As of December 27, 2025, the Company has characterized its Biotechnology segment as a discontinued operation on its financial statements, as follows: on May 21, 2025, the Company announced the planned formal separation of its healthcare assets, known as Drew, and noted that the scope and method of a partial or full disposition, whatever the methodology, would be determined and announced at a later date. On July 29, 2026, the Company agreed to sell ALT5 Canada; the sale closed on August 3, 2026. Accordingly, the operations of the Alt5 Canada have also been included in discontinued operations as of December 27, 2025.

 

The comparative December 27, 2025 balances have been reclassified to include ALT5 Canada with Biotechnology in discontinued operations. The reclassification changes the location of assets and liabilities but does not change total assets, total liabilities, mezzanine equity or stockholders’ equity. The following table presents the assets and liabilities of discontinued operations (in $000s).

 

Schedule Of Discontinued Operations

  September 26, 2026  December 27, 2025 
Assets from discontinued operations        
Cash and cash equivalents  —   3,953 
Trade and other receivables, net  —   140 
         
Digital assets receivable  —   17,997 
Prepaid expenses and other current assets $—  $2,300 
Total current assets from discontinued operations  —   24,390 
Property and equipment, net 1  1,170   1,170 
Intangible assets, net 2  12,540   29,584 
Deferred income taxes  371   1,027 
Goodwill, right-of-use assets and other assets  —   4,193 
Total other assets from discontinued operations  14,081   35,974 
Total assets from discontinued operations $14,081  $35,974 
Liabilities from discontinued operations        
Accounts payable $96  $486 
Accrued liabilities - other 3  1,500   3,349 
Digital assets payable  —   28,693 
Convertible debentures  —   563 
Current operating lease liabilities  —   5 
Total current liabilities from discontinued operations  1,596   33,096 
Total noncurrent liabilities from discontinued operations  —   607 
Total liabilities from discontinued operations $1,596  $33,703 

 

1The Company’s property and equipment consisted of the following (in $000s):

2The Company’s intangible assets consisted of the following (in $000s):
3The Company’s accrued liabilities consisted of the following (in $000s):

 

 

  September 26, 2026  December 27, 2025 
Projects under construction $1,170  $1,170 
Property and equipment  1,170   1,170 
Property and equipment, gross  1,170   1,170 
Less accumulated depreciation  —   — 
Total property and equipment, net, from discontinued operations $1,170  $1,170 

 

Nodepreciation expense has been recorded for the 13 weeks ended September 26, 2026, and September 27, 2025, or the 39 weeks ended September 26, 2026, and September 27, 2025.

 

14
 

 

2The Company’s intangible assets consisted of the following (in $000s):

 

  September 26, 2026  December 27, 2025 
Soin intangible $19,293  $19,293 
Intangible assets  19,293   19,293 
Less accumulated amortization  (6,753)  (5,467)
Soin intangible assets, net  12,540   13,826 
ALT5 Canada intangible assets, net  —   15,758 
Total intangible assets $12,540  $29,584 

 

Biotechnologyamortization expense was approximately $1.3 million and $1.4 million for the thirty-nine weeks ended September 26, 2026 and September 27, 2025, respectively.

 

Soin Intangible Assets

 

Effective as of December 28, 2022, the Company acquired Soin Therapeutics LLC, a Delaware limited liability company (“STLLC”), and its product, a patent-pending, novel formulation of low-dose naltrexone. The assets acquired by the Company consist of 1) three pending patents related to the methods of using low-dose Naltrexone to treat chronic pain, 2) final formula for Naltrexone, and 3) orphan drug designation as approved by the FDA. The Company reviewed the assets acquired and determined that no in-process research and development costs were acquired as part of the transaction, and, thus, all assets acquired represent intellectual property and should be capitalized. The Company will amortize the intangible assets ratably over a ten (10)-year period.

 

3The Company’s accrued liabilities consisted of the following (in $000s):

 

  September 26, 2026  December 27, 2025 
Due to Dr. Soin $1,500  $2,500 
ALT5 Canada accrued liabilities $—  $849 
Total accrued expenses $1,500  $3,349 

 

The results of ALT5 Canada and the Biotechnology business are presented within discontinued operations for all periods shown. The following table presents the thirteen- and thirty-nine-week results for September 26, 2026, and September 27, 2025 (in $000s). The comparative reclassification does not change consolidated net income.

 

                 
  13 Weeks Ended  39 weeks Ended 
  September 26, 2026  September 27, 2025  September 26, 2026  September 27, 2025 
Revenues $596  $6,662  $7,035  $18,232 
Cost of revenues  20   4,487   989   10,689 
Gross profit  576   2,175   6,046   7,543 
Operating expenses from discontinued operations:                
Selling, general and administrative expenses  (84)  8,645   5,483   16,409 
Total operating expenses from discontinued operations  (84)  8,645   5,483   16,409 
Operating income (loss) from discontinued operations  660   (6,470)  563   (8,866)
Other income (expense) from discontinued operations  (9,603)  2,560   (15,889)  (1,106)
Total other income (loss), net  (9,603)  2,560  $(15,889) $(1,106)
Loss before provision for income taxes from discontinued operations  (8,943)  (3,910)  (15,326)  (9,972)
Income tax benefit (provision)  (599)  5,564   (494)  5,390 
Net income (loss) from discontinued operations $(9,542) $1,654  $(15,820) $(4,582)

 

15
 

 

In accordance with the provisions of ASC 360-10 and ASC 205-20, the Company has separately reported the cash flow activity of the discontinued operations in the consolidated statements of cash flows. The cash flow activity from discontinued operations for the 39 weeks ended September 26, 2026 and September 27, 2025, has been reflected as discontinued operations in the consolidated statements of cash flows and consists of the following (in $000s):

 

         
  39 weeks ended 
  September 26, 2026  September 27, 2025 
DISCONTINUED OPERATING ACTIVITIES:        
Net loss from discontinued operations $(15,820) $(4,582)
Depreciation and amortization  2,181   1,126 
Other noncash and working-capital adjustments  8,609   429 
Change in deferred taxes  494   3,057 
Changes in assets and liabilities:        
Prepaids and other current assets  —   — 
Accounts payable and accrued expenses  (999)  (30)
Net cash provided by (used in) operating activities from discontinued operations $(5,535) $— 
DISCONTINUED INVESTING ACTIVITIES:        
Net cash used in investing activities from discontinued operations $(1,024) $— 
DISCONTINUED FINANCING ACTIVITIES:        
Net cash used in financing activities from discontinued operations $— $— 

 

Cash paid for interest during the thirty-nine weeks ended September 26, 2026, totaled $1,495,653, of which $1,235,408was attributable to continuing operations and $260,245to discontinued operations.

 

Sale of ALT5 Sigma Canada, Inc.

 

On July 29, 2026, the Company and its first tier, wholly -owned subsidiary, Alt 5 Sigma, Inc. (a Delaware corporation referenced in Note 1 as the “ALT5 Subsidiary”), entered into an Acquisition Agreement with Prime Delta Corp., a Delaware corporation (“Prime Delta”), pursuant to which the Alt 5 Subsidiary sold to Prime Delta all of the issued and outstanding shares of Alt 5 Sigma Canada, Inc. (“Alt 5 Canada”; referenced in these Notes as our indirect, wholly-owned second tier Canadian subsidiary), through which the Company conducted its payments business. In exchange, the Company received the following consideration: (i) a four (4)-year secured promissory note (the “Prime Delta Note”) in the initial principal amount of $12.0million, bearing interest at 4% per annum, with interest payments due on the 10th day of each month, $1.0million of principal payable on or before August 11, 2026, and the remaining principal payable in four equal annual installments of $2,750,000(all subject to early payments in amounts no less than twenty percent (20%) of the net amounts received by Prime Delta from third-party investors of Prime Delta), and (ii) 11,551,750newly issued shares of Prime Delta common stock (“Prime Delta Stock”). The Company valued the Prime Delta Note at its net present value of $9,251,847, using a market interest rate of 18%, less a Current Expected Credit Losses (CECL) discount of $5,876,847, for a net value of $3,375,000. The fair market value of the Prime Delta’s issued common stock is zero, as there is no readily ascertainable market for such shares. Accordingly, the aggregate fair market value of the consideration received is $3,375,000. The consolidated disposal calculation reflects assets of $24.7million and liabilities of $11.9million, or net assets of $12.8million, before the $0.7million disposal-date deferred-tax adjustment and the $1.7million settlement of intercompany funding payable to Alyea. The adjusted consolidated net assets disposed of were $10.4million. After deducting $3.4million of consideration and releasing $2.6million of cumulative translation losses, the Company recognized a disposal loss of $9.6million in discontinued operations. The transaction closed on August 3, 2026.

 

The Prime Delta Note is secured by substantially all of the assets of Prime Delta and is guaranteed by certain affiliates of Prime Delta. In connection with the transaction, the Company assigned to Prime Delta the “Alt 5” and “Alt 5 Sigma” trademarks and related rights, agreed to cease use of those names, and agreed to change the names of its subsidiaries whose legal names include “Alt 5” within 90 days following the closing.

 

Additionally, through counsel for Prime Delta, the Company may offer the holders of its Series B Preferred Stock the opportunity to redeem their shares of Series B Preferred Stock, on a consensual basis, in exchange for their pro rata share of up to 8,551,750 shares of Prime Delta Stock, on a one share of Series B Preferred Stock for one share of Prime Delta Stock basis. No such redemption offer has commenced, and no documentation has been prepared or filed, as applicable.

 

Note 5: Trade and other receivables

 

The Company’s trade and other receivables as of September 26, 2026 and December 27, 2025, respectively, were as follows (in $000’s):

Schedule of Trade and Other Receivables 

  September 26, 2026  December 27, 2025 
Other receivables $1,818  $2,152 
Trade and other receivables, net $1,818  $2,152 

 

16
 

 

Note 6: Prepaids and other current assets

 

Prepaids and other current assets as of September 26, 2026 and December 27, 2025 consist of the following (in $000’s):

 

Schedule of Other Current Assets

  September 26, 2026  December 27, 2025 
Prepaid interest $500  $— 
Prepaid insurance  433   2 
Prepaid other  157   272 
Total prepaid expenses and other current assets $1,090  $274 

 

Note 7: Property and Equipment

 

Property and equipment as of September 26, 2026 and December 27, 2025 consist of the following (in $000’s):

Schedule of Property and Equipment 

  September 26, 2026  December 27, 2025 
Furniture and fixtures $43  $43 
Computer equipment  22   22 
Property and equipment  65   65 
Property and equipment gross  65   65 
Accumulated depreciation  (42)  (37)
Total property and equipment, net $23  $28 

 

Note 8: WLFI Treasury Program

 

The WLFI treasury program was initiated on August 12, 2025, with purchases executed in two tranches at $0.20 per token:

 

 ●Tranche 1: 3,750,000,000 WLFI tokens
   
 ●Tranche 2: 3,584,000,000WLFI tokens (adjusted slightly from initial 3,750,000,000 to reflect final settlement after expenses from the proceeds of the financing completed in August 2025 (~7.3% of supply).

 

All acquisitions were executed through on-chain transactions and direct Token Purchase Agreements with the WLFI Foundation. The Company did not hold any WLFI tokens prior to August 12, 2025.

 

The outstanding units, cost basis, and fair value as of September 26, 2026 were as follows (in $000’s, except for units):

Schedule of Outstanding Units, Cost Basis and Fair Value 

  Units  Cost Basis  Fair Value 
Balance, September 26, 2026:            
WLFI  7,283,585,650  $1,456,717  $417,441 
Total  7,283,585,650  $1,456,717  $417,441 

 

The following table presents a reconciliation of WLFI assets to fair value as of September 26, 2026 (in $000’s):

Schedule of Reconciliation of WLFI Assets to Fair Value 

  September 26, 2026 
Fair value, December 27, 2025 $1,054,663 
Fair value, beginning balance $1,054,663 
Additions  — 
Redemptions  — 
Fees paid  — 
Subtotal  1,054,663 
Unrealized loss  637,222 
Fair value, September 26, 2026 $417,441 
Fair value, ending balance $417,441 

 

During the 39 weeks ended September 26, 2026, the Company recognized an unrealized loss of approximately $637.2 million related to the change in fair value of the tokens.

 

17
 

 

Concrete Agreement

 

Alt5 Digital Holdings, Inc. entered into a two-year arrangement with related party Concrete Network Services Ltd. under a Master Services Agreement and Statement of Work dated July 13, 2026; the relationship is described in Note 21. The Company retains legal and beneficial title to the delegated WLFI tokens and continues to recognize them at fair value, including $114.5 million pledged in the Concrete Prime and Core wallets at September 26, 2026; collateral may be sold or repledged, and withdrawal requires satisfaction of the contractual repayment and release conditions. Concrete delivered a $3.0 million USDC client advance on August 3, 2026, and the Company guarantees any repayment shortfall through the contractual yield waterfall. The Company also bears Qualified Losses on Concrete’s Prime portfolio, approximately $28.2 million at quarter end, including any contractual deficiency exposure; no such losses were reported through October 13, 2026, and no additional Qualified Losses liability has been recorded.

 

At September 26, 2026, pledged WLFI assets totaled $136.2 million, comprising $114.5 million in the Concrete arrangement and $21.7 million pledged for other WLFI collateralized loans. These assets are presented separately from $281.2 million of unpledged WLFI assets; aggregate recognized WLFI fair value is $417.4 million. Loan collateral remains restricted until the relevant secured obligations and release conditions are satisfied. Of the unpledged holdings, the segregated second-tranche wallet had a fair value of approximately $75.9 million and remains subject to contractual release requirements, including registration effectiveness where applicable; expiration of the twelve-month holding period alone does not satisfy all release conditions. The remaining unpledged holdings remain subject to their applicable transfer and withdrawal arrangements.

 

Note 9: Intangible Assets

 

Intangible assets as of September 26, 2026 and December 27, 2025 consist of the following (in $000’s):

Schedule of Intangible Assets 

  September 26, 2026  December 27, 2025 
Noncompete agreements $675  $675 
Qoden intangible  —   — 
Patents and domains  4   4 
Trade names  500   500 
Customer relationships  6,525   6,525 
Block Street intangible  11,729   — 
Developed technology  —   — 
Intangible assets  19,433   7,704 
Total intangible assets gross  19,433   7,704 
Less accumulated amortization  (898)  (422)
Total intangible assets $18,535  $7,282 

 

Intangible amortization expense from continuing operations was approximately $0.476 million for the thirty-nine weeks ended September 26, 2026. The carrying amount of continuing intangible assets at September 26, 2026, was approximately $18.5 million. ALT5 Subsidiary amortization is included in discontinued operations for the periods presented.

 

Block Street

 

Effective on April 20, 2026, the Company entered into an agreement to purchase all of the outstanding capital stock of Block Street which operates a platform designed to support token issuances aligned with applicable regulatory frameworks and the tokenization of real-world assets. Block Street’s capabilities have not yet been deployed commercially and Block Street has not generated revenues to date. The Company will amortize the intangible assets over a ten (10)-year period when the assets are placed in service (see Note 3).

 

Mswipe

 

Effective on May 9, 2025, the Company and our indirect, wholly-owned second tier Canadian subsidiary entered into an agreement to purchase all of the outstanding capital stock of an entity that, through its subsidiaries, offers multi-currency, fiat- and crypto-enabled payment card services (see Note 3).

 

Qoden Intangible Assets

 

On November 8, 2024, the Company acquired the Qodex Cryptocurrency Exchange Software platform and other related assets from Qoden Technologies, LLC, a provider of technology solutions for the blockchain industry. The Company was planning to amortize the intangible assets over a two 2 (2)-year periods (see Note 3). However, the intangible assets were sold as part of sale of ALT5 Canada during the 13 weeks ended September 26, 2026.

 

ALT5 Subsidiary Intangible Assets

 

On May 14, 2024, the Company acquired its ALT5 Subsidiary, which is a fintech company that provides next generation blockchain-powered technologies to enable a migration to a new global financial paradigm. As part of the acquisition, the Company acquired trade names, customer relationships, and developed technology, which were originally planned to be amortized over a period of seven years,10 years, and five years, respectively (see Note 3). However, the intangible assets were sold as part of sale of ALT5 Canada during the 13 weeks ended September 26, 2026.

 

Note 10: Goodwill

 

The following table details the Company’s goodwill as of September 26, 2026 and December 27, 2025 (in $000’s):

Schedule of Goodwill 

  Fintech  Biotech  Corporate and Other  Total 
December 27, 2025  12,297   —   —   12,297 
Goodwill disposed of with ALT5 Canada  (3,880)  —   —   (3,880)
September 26, 2026 $8,417  $—  $—  $8,417 

 

Total goodwill at December 27, 2025 was $12.3 million, comprising $8.4 million in continuing Fintech operations and $3.9 million included within assets from discontinued operations attributable to ALT5 Canada. The sale of ALT5 Canada removed the latter amount during 2026. The goodwill reconciliation above includes both classifications.

 

The Company accounts for purchased goodwill and intangible assets in accordance with ASC 350, Intangibles—Goodwill and Other. Goodwill recognized during the 39 weeks ended September 27, 2025 was approximately $8.4 million, and was due to the acquisition of Mswipe (see Note 3).

 

18
 

 

Note 11: Accrued Liabilities

 

Accrued liabilities as of September 26, 2026 and December 27, 2025 consist of the following (in $000’s):

Schedule of Accrued Liabilities 

  September 26, 2026  December 27, 2025 
Compensation and benefits $231  $328 
Accrued guarantees  —   300 
Accrued settlements  —   4,002 
Accrued interest  48  179 
Accrued professional fees  —   86 
Accrued Qoden payments  —   — 
Accrued litigation/legal  660   660 
Customer deposits  —   1,200 
Other  2,959   934 
Total accrued expenses $3,898  $7,689 

 

Note 12: Debentures

 

Debentures outstanding as of September 26, 2026, and December 27, 2025, consisted of the following (in $000’s):

 Schedule of Debenture Outstanding

  September 26, 2026  December 27, 2025 
Interest rate of 12%, maturity date of June 30, 2025 $75  $563 
Interest rate of 12%, maturity date of June 30, 2025 $75  $563 
Total debentures $75  $563 

 

ALT5 Subsidiary issued seven debentures over a period from October 2018 through September 2019. The debentures bear interest at 12% per annum and matured on June 30, 2025.

 

During March 2026, six of the debentures, representing approximately $0.5 million of the aggregate principal amount, were settled through the issuance of 114,328 shares of the Company’s common stock. The remaining balance is currently being negotiated for settlement with the sole remaining holder.

 

Note 13: Debt

 

At September 26, 2026, the Company had a $2,999,539 noncurrent advance from Concrete under the July 13, 2026 arrangement described in Note 8. The $3.0 million advance was delivered on August 3, 2026, and is repayable through the contractual deployment yield waterfall. Alt5 Digital guarantees any shortfall. Withdrawal of pledged collateral is subject to the applicable repayment and release conditions.

 

Long-term debt as of September 26, 2026, and December 27, 2025, consisted of the following (in $000’s):

 Schedule of Long-Term Debt

  September 26, 2026  December 27, 2025 
Fixed deposits $7,460  $7,937 
WLFI loan  15,000   — 
Unaffiliated third-party  —   310 
Seller notes  4,654   5,944 
Concrete client advance  3,000   — 
Insurance premium financing  393   — 
Total notes payable  30,507   14,191 
Less current portion  (12,507)  (5,944)
Total long-term notes payable $18,000  $8,247 

 

Fixed Deposits

 

The Company entered into Corporate Fixed Deposit Agreements with unaffiliated third parties bearing interest at 13% or 15% per annum. Outstanding obligations were approximately $7.5 million and $7.9 million at September 26, 2026 and December 27, 2025, respectively. All September 26, 2026 balances mature by March 2027 and are classified as current notes payable. No qualifying extension or refinancing has been reflected in that classification. Insurance premium financing of $0.4 million relates to the July 2026–June 2027 policy period and monthly repayments and is also classified as current.

 

WLFI Loan Agreement

 

On January 29, 2026, we, through our indirect, wholly-owned subsidiary, ALT5 Digital Holdings, Inc. (“ALT5 Digital” or the “Borrower”), entered into a Master Loan and Security Agreement (the “Loan Agreement”) with WLFI. Zachary Witkoff, Chairman of our Board, is the Chief Executive Officer and Co-Founder of WLFI, and Zachary Folkman, a member of our Board, is the Co-Founder of WLFI.

 

The Loan Agreement provides for collateralized loans in the aggregate principal amount of $15.0 million. Pursuant to the Loan Agreement, the loan will accrue interest at a rate of 4.50% per annum, payable annually in advance beginning on the applicable closing date. The principal amount and any accrued but unpaid interest under the loan are due on the maturity date, which is 24 months from the closing date of the initial loan under the Loan Agreement. The Loan Agreement is a secured, non-recourse facility to the Borrower and to us. As security for the obligations under the loan, we granted WLFI a security interest in, and transferred legal title and custody of, $WLFI tokens owned by the Borrower (the “Collateral”). The loan-to-value ratio is 65% of the pledged Collateral, which, for a $15.0 million loan, would consist of approximately $23.0 million in value of free-trading, unrestricted WLFI tokens. There are no origination, management, or prepayment fees, although the Borrower is responsible for WLFI’s expenses. Events of default include, among others, failure to pay interest when due, failure to satisfy margin top-up requirements after a margin call, breaches of covenants or representations that remain uncured after notice, and certain insolvency events. Following an event of default, the entirety of the Collateral for the loan will be forfeited to WLFI.

 

19
 

 

The Loan Agreement includes customary representations, warranties, covenants, risk disclosures relating to digital asset collateral, and other terms and conditions customary for transactions of this type, including provisions regarding public disclosure, successor and assignment rights, modification and waiver, notices, and interpretation. The governing law for the Loan Agreement and related documents (other than UCC matters) is the law of the State of Delaware, and disputes are subject to binding arbitration administered by the International Centre for Dispute Resolution seated in Miami, Florida.

 

On January 29, 2026, the Borrower drew the $15.0 million facility in one tranche. Portions of the proceeds were applied to prepaid interest, funding-related professional fees, and other custody uses before funds were released to bank accounts. The intended use of proceeds was to pursue a stock buyback program approved by the Board.

 

As of March 28, 2026, the Company pledged 220,620,679 WLFI, with an additional 157,689,435 pledged in the 13 weeks ended September 26, 2026, for a total of 378,310,114 WLFI tokens as collateral as of September 26, 2026.

 

Unaffiliated Third-Party Loans

 

ICG Note

 

On February 7, 2024, the Company amended its outstanding related party promissory obligations (the “ICG Note”) in favor of Isaac Capital Group LLC (“ICG”) to add a convertibility provision. In accordance with Nasdaq Rules, the per-share conversion price was set at $0.61, subject to standard adjustments for (i) stock dividends and splits, (ii) subsequent rights offerings, and (iii) pro rata distributions. The Company’s board of directors provided its approvals of the amendments on February 7, 2024. On March 6, 2024, ICG entered into a Note Purchase Agreement with an otherwise unaffiliated third party, under which the third party acquired the ICG Note. The terms and conditions of the ICG Note were not modified in connection with its acquisition by the third party. The principal amount of the ICG Note on the date of acquisition was approximately $1.2 million. As of September 27, 2025, the third party had converted $872,000 of the Company’s obligations under the ICG Note into 1.4 million shares of the Company’s common stock. As of September 26, 2026, and December 27, 2025, the amount outstanding on the ICG Note was approximately $0 and $26,000, respectively.

 

Big/Small Debentures

 

On August 20, 2024, the Company entered into three Purchase Agreements with three otherwise unaffiliated third-party investors (the “Investors”), pursuant to which (1) one Investor agreed to purchase a unit (the “Unit”), consisting of (i) a non-convertible debenture in the principal amount of up to approximately $1.8 million (the “Big Debenture”), and (ii) a warrant (the “Big Warrant”) for the purchase of up to 400,000 shares of the Company’s Common Stock and (2) the two other Investors each agreed to purchase a Unit, consisting of (i) a non-convertible debenture in the principal amount of up to $404,454 (the “Small Debenture”, and, together with the Big Debenture, the “Debentures”) and (ii) a warrant (the “Small Warrant”, and, together with the Big Warrant, the “Warrants”) for the purchase of up 90,909 shares of Common Stock.

 

The Debentures are unsecured and subordinated to any existing or future debt. The Debentures bear interest at a rate of (i) 1% per month from and after August 20, 2024 (“Original Issue Date”) through and including October 31, 2024, (ii) 3% per month from and after November 1, 2024 through and including January 29, 2025, and (iii) 4% per month from and after January 30, 2025 through and including the date of repayment.

 

The Big Debenture was issued with an original issue discount (an “OID”) initially of $171,000, which OID can be expanded with up to two potential additions, the first in the amount of $171,000 and, thereafter, in the amount of $342,000, which OIDs will increase the principal amount owing on the Big Debenture. With the original OID, the initial principal amount owing under the Big Debenture is approximately $1.3 million; if, expanded, the principal amount would increase to approximately $1.4 million and, thereafter, potentially to approximately $1.8 million. The first potential increase in the Big Debenture OID would occur if the initial principal amount and interest accrued thereon is not paid in full on or before October 31, 2024. The second potential increase in the OID would occur if the initial principal amount (including the first potential increase in the OID) and interest accrued thereon is not paid in full on or before January 29, 2025.

 

The Small Debentures were issued with an OID initially of $38,863, which OID can be expanded with up to two potential additions, the first in the amount of $38,863 and, thereafter, in the amount of $77,728, which OIDs will increase the principal amount owing on the Small Debentures. With the original OID, the initial principal amount owing under a Small Debenture is $288,864; if, expanded, the principal amount would increase to $327,726 and, thereafter, potentially to $404,454. The first potential increase in the Small Debenture OID would occur if the initial principal amount and interest accrued thereon is not paid in full on or before October 31, 2024. The second potential increase in the OID would occur if the initial principal amount (including the first potential increase in the OID) and interest accrued thereon is not paid in full on or before January 29, 2025.

 

20
 

 

As of November 1, 2024, the first of the two additional OIDs was effective. The final maturity date for each of the Debentures is April 28, 2025.

 

The Big Warrant is exercisable, at an exercise price of $1.71 per share, as follows: (i) 100,000 shares of Common Stock as of Original Issue Date, (ii) contingently for an additional 100,000 shares of Common Stock as of October 31, 2024, if, as of such date, the Company has not repaid in full its obligations under the Big Debenture, and (iii) contingently for an additional 200,000 shares of Common Stock as of January 29, 2025, if, as of such date, the Company has not repaid in full its obligations under the Big Debenture. The Company and the holder of the Big Warrant reached an agreement, pursuant to which the term of the final tranche of the Big Warrant was extended to August 20, 2027, the number of underlying shares was reduced to 192,982 shares of Common Stock, and the exercise price of $1.71 per share was unchanged.

 

The Small Warrant is exercisable, at an exercise price of $1.71 per share, as follows: (i) 22,727 shares of Common Stock as of Original Issue Date, (ii) contingently for an additional 22,727 shares of Common Stock as of October 31, 2024, if, as of such date, the Company has not repaid in full its obligations under the Small Debenture, and (iii) 45,455 shares of Common Stock as of January 29, 2025, if, as of such date, the Company has not repaid in full its obligations under the Small Debenture.

 

As of November 1, 2024, the contingent second tranche of the Warrants vested.

 

Except as disclosed with respect to the final tranche of the Big Warrant, each Investor is required to exercise the initial tranche of each Warrant within 15 days of the Original Issue Date. Upon the vesting of each contingent tranche of a Warrant vest, each Investor shall exercise such vested, contingent tranche within 15 days of the vesting of such contingent tranche. If the Company consummates any equity or debt financing before satisfying in full its obligations under the Debentures, then 50% of every net dollar received by the Company from any such financing transaction shall be paid by the Company to the holders of the Debentures, on a pro rata basis, as a mandatory pre-payment thereof. In the event the Company has repaid all sums owing under a Debenture to the Investor, except for an amount equal to any non-conditional OID, the Company has the right, not the obligation, to exercise the vested portion of the Warrant held by the Debenture holder through a set-off of any or all such unpaid OID, on a dollar-for-dollar basis. The Warrants also feature a “cashless” exercise provision. In lieu of making the cash payment otherwise contemplated to be made to the Company upon exercise of a Warrant in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of Common Stock determined according to a formula set forth in the Warrant.

 

During the quarter ended September 27, 2025, one of the two non-affiliated Investors exercised the remainder of the Small Warrant for a total of 45,455 shares (see Note 16). During the fourth quarter of the year ended December 28, 2024, the non-affiliated Investor exercised the Big Warrant for a total of 200,000 shares of the Company’s common stock, and the other two non-affiliated Investors exercised the Small Warrant for a total of 90,908 shares. Additionally, during the fourth quarter of the year ended December 28, 2024, these unaffiliated third-parties agreed to convert a portion their respective investment into Future Equity Agreements of the Company’s subsidiary, Drew and, consequently, approximately $1.3 million was reclassified as non-controlling interest. During the 13 weeks ended September 27, 2025, the Company paid approximately $0.2 million, in principal and accrued interest, to one of the two non-affiliated Investors in settlement of its debt. As of September 26, 2026 and December 27, 2025, the outstanding balance due on the debentures was approximately $0 and $0.3 million, respectively, consisting of principal and accrued interest.

 

Amendments to Promissory Notes and Warrants

 

Effective July 7, 2026, the Company entered into Extension and First Amendment Agreements with the holders of ten promissory notes with an aggregate principal amount of CAD$2,750,000, pursuant to which the maturity dates of the notes were extended to October 1, 2026 in consideration of the payment of extension fees equal to 1.75% of the principal amount of each note, or CAD$48,125 in the aggregate. In connection with the extensions, the Company amended warrants held by five of the noteholders to purchase an aggregate of 340,000 shares of the Company’s common stock, to reduce the per-share exercise prices of each from $2.25 to $1.00 and to extend their expiration date from May 15, 2027 to December 31, 2027.

 

Note 14: Commitments and Contingencies

 

Litigation

 

SEC Complaint

 

On August 2, 2021, the U.S. Securities and Exchange Commission (“SEC”) filed a civil complaint (the “SEC Complaint”) in the United States District Court for the District of Nevada naming the Company and one of its executive officers, Virland Johnson, the Company’s Chief Financial Officer, as defendants (collectively, the “Defendants”). Pursuant to an agreed-upon Order of the Court, on May 28, 2024, the Company settled its litigation with the SEC. The Company’s Settlement Agreement provided, in pertinent part: “Without admitting or denying the allegations of the complaint (except as provided herein in paragraph 12 and except as to personal and subject matter jurisdiction, which [the Company] admits), [the Company] hereby consents to the entry of the final Judgment in the form attached hereto (the “Final Judgment”) and incorporated by reference herein, which, among other things: “(a) permanently restrains and enjoins [the Company] from violation of Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder [15 U.S.C. § 78j(b) and 17 C.F.R. §§ 240.10b-5]; and (c)[sic] orders [the Company] to pay a civil penalty in the amount of $250,000under Section 21(d)(3) of the Exchange Act [15 U.S.C. § 78u(d)(3)).” The SEC has agreed to accept four quarterly payments from the Company, each in the amount of $62,500. The Settlement Agreement is attached to the Order as Exhibit 1, both of which documents may be viewed at https://ecf.nvd.uscourts.gov/doc1/115110470966.

 

21
 

 

Pursuant to a Joint Motion filed by the SEC and Mr. Johnson, among others, and upon an Amended Final Judgment of the Court, on August 26, 2026, Mr. Johnson’s litigation with the SEC was settled. Mr. Johnson’s accepted Offer of Settlement provided, in pertinent part: “Solely for the purpose of these proceedings and any other proceedings brought by or on behalf of the Commission or in which the Commission is a party, and without admitting the findings contained in the Order, except with respect to the findings contained in paragraph 3 below, which are admitted, consents to the entry of an Order by the Commission . . .” Paragraph 3 thereof provided, “… the court entered an order permanently enjoining Johnson, by consent, from future violations of Exchange Act Rule 13b2-2 [17 C.F.R. § 240.13b2-2], as set forth in the judgment entered in the civil action entitled Securities and Exchange Commission v. Live Ventures, et al., Civil Action Number 2:21-cv-01433-JCM-MDC, in the United States District Court for the District of Nevada. Johnson was also ordered to pay a $118,225 civil money penalty.”

 

Sieggreen

 

In a matter pending in the United States District Court for the District Of Nevada, Case No. 2:21-cv-01517-CDS-EJY, styled as Sieggreen, Individually and On Behalf of All Others Similarly Situated, Plaintiff, v. Live Ventures Incorporated, Jon Isaac, and Virland A. Johnson, Defendants, the Company was added as a defendant on March 6, 2023, and was served on March 23, 2023. Plaintiff has alleged causes of action against the Company for (i) violation of Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder and (ii) violation of Section 10(b) of the Securities Exchange Act of 1934 and Rules 10b-5(a) and 10b-5(c) promulgated thereunder. In June 2023 the Company filed a Motion to Dismiss, which the Court granted with leave for Plaintiffs to file a second amended complaint. Plaintiffs filed their Second Amended Complaint on October 31 2024. On December 16, 2024, the Company filed a Motion to Dismiss, which the Court denied. Thereafter, the Company filed an answer to the Second Amended Complaint. The Company strongly disputes and denies all of the allegations contained therein and will continue to defend itself vigorously against the claims.

 

Main/270

 

The Company is a defendant in an action filed on April 11, 2022, in the U.S. District Court Southern District of Ohio, Eastern Division, styled, Trustees Main/270, LLC, Plaintiff, vs ApplianceSmart, Inc. and JANONE, Inc., Defendant, Case No.: 2:22-cv-01938-ALM-EPD. In November 2026, the parties reached a settlement agreement in this matter, pursuant to which the Company agreed to pay to the plaintiff approximately $1.675 million in a series of payments. The first payment is due in early November 2026 in the amount of $150,000; the second payment is due in early December 2026 in the amount of $100,000; the next 27 payments, each in the amount of $50,000 commence in early January 2027 through early April; the final last payment in the approximate amount of 25,000 is due in early May 2029.

 

Gulf Coast Bank and Trust vs. ALT5 Sigma Corporation, et al.

 

In a matter in the United States District Court for the State of Minnesota, Hennepin County, Case No. 27-CV-24-340, styled as Gulf Coast Bank and Trust Company, Plaintiffs, v ARCA Recycling, Inc., JanOne Inc., and Virland A. Johnson, Defendants; plaintiff sought the payment of approximately $1.6 million (inclusive of principal, interest, and attorneys’ fees) related to the Company’s guarantee of certain obligations of ARCA Recycling Inc., a prior subsidiary of the Company. In the context of the collection litigation, the Company posted a $900,000 cash bond with the Court. In connection with Gulf Coast Bank’s foreclosure on the assets of ARCA Recycling, the Company asserted that Gulf Coast did not act in a commercially reasonable manner regarding its monetizing ARCA’s accounts receivable, inventory, and equipment, which actions resulted in substantial loss of collateral value. The parties reached a settlement agreement under which the Company agreed to pay the Plaintiff a total of $975,000, funded through the $900,000 cash bond and a $75,000 cash payment that was tendered on December 1, 2025.

 

Virland Johnson Bankruptcy

 

On August 14, 2025, the Company received a Summons and Complaint in an Adversary Proceeding (the “Complaint”) filed on August 6, 2025 in connection with the Chapter 7 bankruptcy proceeding titled In re Virland Johnson, No. 2:24-bk-00226-BKM, pending in the United States Bankruptcy Court for the District of Arizona and involving the Company’s former Chief Financial Officer, Virland Johnson. The Complaint alleges that Mr. Johnson had been awarded in October 2023 restricted stock units entitling him to receive 329,294shares of the Company’s common stock under the Company’s 2023 Equity Incentive Plan. According to the Complaint, Mr. Johnson did not disclose the existence of the stock award in his January 11, 2024 Chapter 7 bankruptcy petition or accompanying disclosure schedules. The Complaint alleges that the common stock may not have been delivered to Mr. Johnson, may have been assigned by Mr. Johnson to the Company or another unknown assignee, may have been sold by Mr. Johnson, or may even continue to be held by Mr. Johnson. Through the Complaint, the U.S. Trustee seeks to recover the common stock or, if it is no longer available, the equivalent value from the Company on behalf of the bankruptcy estate. On September 30, 2025 the Company filed its Answer to the Complaint and denied the allegations of any wrongdoing by the Company. The Company disputes the allegations concerning the Company and will continue to defend itself vigorously against the claims.

 

22
 

 

First Capital Consulting, Inc. DBA Trusaic vs. ALT5 Sigma Corporation

 

In a matter in the Los Angeles, California Superior Court Case No. 24STCV02261, styled as First Capital Consulting, Inc., Plaintiff v ALT5 Sigma Corporation, ARCA Recycling, Inc., Customer Connexx LLC; and DOES 3 through 10, inclusive, Defendants; plaintiff was seeking $97,696, plus costs and interest, against the Company for unpaid obligations of entities that no longer exist or do not have any assets, i.e., ARCA Recycling Inc. and Customer Connexx LLC. Plaintiff alleges that ALT5 Sigma Corporation, as the parent company at the time was then known, should be responsible for the fees. Plaintiff filed a motion for summary judgment on March 5, 2026, which the Court granted on June 2, 2026. In October 2026, we reached an agreement with plaintiff, pursuant to which we agreed to pay the sum of $100,000in three substantially equal payments that commenced in mid-October and continue for the two succeeding 30-day periods, the aggregate sum of which represents a one-third reduction from the approximately $150,000 that plaintiff was seeking for its judgment of $97,690and $52,887of attorneys’ fees.

 

Judgment in Rwanda

 

ALT5 Sigma Canada, Inc., formerly an indirect wholly-owned subsidiary of the Company, was sold to Prime Delta Corp. on August 3, 2026. The former subsidiary is the subject of proceedings in Rwanda concerning US$3.5million held in its account at I&M Bank. Following the disposal, the Company no longer owns ALT5 Sigma Canada, Inc. or any interest therein and, accordingly, no longer has an economic interest in the Rwanda matter or the funds at issue. The former subsidiary and the related assets are no longer included in the Company’s consolidated balance sheets.

 

Other Commitments

 

On December 30, 2017, the Company disposed of its retail appliance segment and sold ApplianceSmart to Live Ventures Incorporated (“Live Ventures”), a related party. In connection with that sale, as of January 1, 2022, the Company accrued an aggregate amount of future real property lease payments of approximately $767,000, which represented amounts guaranteed or which may have been owed under certain lease agreements to three third-party landlords in which the Company either remained the counterparty, was a guarantor, or had agreed to remain contractually liable under the lease (“ApplianceSmart Leases”). A final decree was issued by the court on February 28, 2022, upon the full satisfaction of the Plan, at which time ApplianceSmart emerged from Chapter 11. During the year ended December 28, 2024, the Company reversed approximately $637,000of the accrual, as the Company is no longer liable for two of these guarantees upon ApplianceSmart’s emergence from bankruptcy. Prior to August 2025, the balance of approximately $130,000was paid, half by the Company and half by Live Ventures. The Company and Live Ventures also agreed to divide in half between them any attorneys’ fees expended in this matter.

 

The Company is party from time to time to other ordinary course disputes that we do not believe to be material to our financial condition as of September 26, 2026.

 

Note 15: Registered Direct Offering

 

Registered Direct Offering

 

On or about August 12, 2025, the Company entered into securities purchase agreements (the “Registered Offering Purchase Agreements”) with certain institutional investors, pursuant to which the Company agreed to issue to the Purchasers (as defined therein), in a registered direct offering (the “Registered Offering”), an aggregate of 100,000,000 shares of the Company’s common stock, par value $0.001 per share (“Common Stock”), at a purchase price of $7.50 per share.

 

The Company intends to use up to $10.0 million of the net proceeds from the Registered Offering to settle existing litigation, pay existing debt, and fund the Company’s existing business operations. The balance of the net proceeds was used to fund the acquisition of $WLFI tokens from World Liberty Financial, Inc. (the “Lead Investor”), pursuant to a Token Purchase Agreement, and the establishment of the Company’s cryptocurrency treasury operations. The shares of Common Stock issued in the Registered Offering were issued pursuant to a prospectus supplement, which was filed with the SEC on August 11, 2025, in connection with a takedown from the Company’s shelf registration statement on Form S-3, as amended, (File No. 333-289176), which was declared effective by the SEC on August 8, 2025.

 

23
 

 

Private Placement Offering

 

Also, on August 12, 2025, the Company consummated transactions resulting from a Securities Purchase Agreement (the “Private Placement Purchase Agreement” and, together with the Registered Offering Purchase Agreements, the “Purchase Agreements”), with the Lead Investor, pursuant to which the Company received $750.0million of $WLFI tokens and issued to the Lead Investor, in a concurrent private placement (the “Private Placement” and together with the Registered Offering, the “Offerings”), 1,000,000shares of Common Stock at a purchase price of $7.50per share (the “PIPE Shares”), and agreed to issue pre-funded warrants (the “PIPE Pre-Funded Warrants”) to purchase up to 99,000,000shares of Common Stock at a purchase price of $7.499per PIPE Pre-Funded Warrant (the “PIPE Pre-Funded Warrant Shares”). Each of the PIPE Pre-Funded Warrants is exercisable for one share of Common Stock at an exercise price of $0.001per share. The PIPE Pre-Funded Warrants were not exercisable until the Company had (i) obtained stockholder approval to allow the issuance of shares underlying the PIPE Pre-Funded Warrants in excess of 19.99% of the shares of common stock outstanding immediately prior to the execution of the Purchase Agreement (the “Exchange Cap”) and (ii) filed an amendment to its Articles of Incorporation to increase the number of authorized shares of common stock (the “Amendment”), both of which occurred in October 2025. The PIPE Pre-Funded Warrants had not been issued as of September 26, 2026 and are excluded from the 2026 earnings-per-share denominators.

 

Pursuant to the Private Placement Purchase Agreement, the Lead Investor was issued Common Stock Purchase Warrants (the “Lead Investor Warrants”) to purchase up to 10% of the number of shares of Common Stock or pre-funded warrants sold in the offering, or 20 million shares of Common Stock. The Lead Investor Warrants are exercisable for (i) 8,000,000 shares of Common Stock at an exercise price of $7.50 per share of Common Stock; (ii) 4,000,000 shares of Common Stock at an exercise price of $8.25 per share of Common Stock; (iii) 4,000,000 shares of Common Stock at an exercise price of $9.00 per share of Common Stock; and (iv) 4,000,000 shares of Common Stock at an exercise price of $9.75 per share of Common Stock, subject to adjustment. The issuance of the shares of Common Stock underlying the Lead Investor Warrants (the “Lead Warrant Shares”) was also subject to stockholder approval of the Exchange Cap and the Amendment, which, as noted above, occurred in October 2025.

 

The issuance and sale of the PIPE Shares, the PIPE Pre-Funded Warrants, the Lead Investor Warrants, and the Lead Investor Shares (collectively, the “PIPE Securities”) were not registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state securities laws. The PIPE Securities were, or will be, as relevant, issued in reliance on the exemption from registration provided by Section 4(a)(2) under the Securities Act and/or Regulation D promulgated thereunder for transactions not involving a public offering. Pursuant to the terms of the Registration Rights Agreement (as defined herein), the Company is required to file a registration statement providing for the resale of the PIPE Securities within 15 days of the closing of the Private Placement. As of the date of this Quarterly Report, the registration statement has not yet been filed.

 

The Registered Offering resulted in gross proceeds of $750 million and the Private Placement resulted in the receipt of $750 million of WLFI tokens, in each case before deducting placement agent commissions and other offering expenses. The closing of the Offerings occurred on August 12, 2025.

 

Pursuant to the Purchase Agreements, the Company has agreed not to issue, enter into any agreement to issue, or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock equivalents, or file any registration statement or any amendment or supplement thereto, for a period of thirty (30) days after the initial registration statement was declared effective, subject to certain customary exceptions, including the use of the Sales Agreement (as defined herein), without the consent of the Purchasers, the Lead Investor, and the Placement Agent.

 

Placement Agency Agreements

 

The Company entered into a Placement Agency Agreement with A.G.P./Alliance Global Partners (the “Placement Agent”), dated August 11, 2025, pursuant to which the Placement Agent acted as the exclusive placement agent for the Company in connection with the Registered Offering (the “RD Placement Agency Agreement”). Pursuant to the RD Placement Agency Agreement, the Company paid the Placement Agent a cash fee of 3% of the gross proceeds from the Registered Offering and issued to the Placement Agent (or its designees) warrants to purchase that number of shares of Common Stock equal to 3% of the securities sold in the Registered Offering, which are exercisable beginning 180 days following the closing date, and have an initial exercise price per share of Common Stock of $8.25 (the “Placement Agent Warrants”). In addition, the Company reimbursed the Placement Agent for up to $475,000 of its fees and expenses, and up to $10,000 in non-accountable expenses, in connection with the Registered Offering.

 

24
 

 

The Company also entered into a Placement Agency Agreement with the Placement Agent, dated August 11, 2025, pursuant to which the Placement Agent acted as the exclusive placement agent for the Company in connection with the Private Placement (the “PIPE Placement Agency Agreement”). Pursuant to the PIPE Placement Agency Agreement, the Company paid the Placement Agent (or its designees) a cash fee of (i) $6.5 million for all tokens paid for the securities sold in the Private Placement in excess of $500 million and (ii) 3% of the gross proceeds of cash paid for the securities sold in the Private Placement Offering by the Placement Agent, and issued to the Placement Agent, Placement Agent Warrants equal to 3% of the securities sold in the Private Placement, which are exercisable beginning 180 days following the closing date, and have an initial exercise price per share of Common Stock of $8.25. In addition, the Company reimbursed the Placement Agent for up to $475,000 of its fees and expenses, and up to $10,000 in non-accountable expenses, in connection with the Private Placement.

 

The issuance of the Placement Agent Warrants and the shares of Common Stock underlying the Placement Agent Warrants (the “Placement Agent Warrant Shares”) will not be registered under the Securities Act or any state securities laws. The Placement Agent Warrant Shares will be issued in reliance on the exemption from registration provided by Section 4(a)(2) under the Securities Act and/or Regulation D promulgated thereunder for transactions not involving a public offering.

 

The Placement Agency Agreement contains customary representations, warranties, and agreements by the Company, customary conditions to closing, indemnification obligations of the Company, other obligations of the parties, and termination provisions.

 

On December 30, 2025, the Company entered into an agreement (the “Placement Agent Subsequent Agreement”) with the Placement Agent that modified certain of the terms of the Placement Agent Agreements. The parties agreed, subject to certain limitations, to extend the Placement Agent’s irrevocable right of first refusal to act as sole investment banker, sole book-runner, sole sales agent, and/or sole placement agent, at its sole discretion, for the Company’s future public and private equity and debt offering, including all equity linked financings, through December 31, 2026, on terms customary to the Placement Agent. The fee tail period, as provided in the Placement Agent Agreements, was also extended from August 12, 2026, through December 31, 2026. In connection with such extensions, the Placement Agent (i) paid the Company the sum of one million dollars and (ii) agreed that, once it has received one million dollars in fees paid to it by the Company with respect to any financing consummated during the extended right of first refusal period or in respect of the extended fee tail period, the Company may allocate 35% of the fees otherwise to be associated therewith to another bank and/or broker-dealer or, if no other bank or broker-dealer would be entitled to any such fees, then the Placement Agent will reduce its customary and reasonable fees associated therewith during such periods by 35%. The Company also generally released the Placement Agent from all claims or other obligations through the date of the Placement Agent Subsequent Agreement. In connection with the Placement Agent Subsequent Agreement, on December 26, 2025, the Company entered into an agreement with Keefe, Bruyette & Woods, Inc. (“KBW”), that superseded and terminated the parties’ May 14, 2025, and June 16, 2025, agreements, which provided that KBW would render certain financial advisory and investment banking services to the Company. Under this agreement, the Company agreed to pay to KBW the sum of three million dollars, one-third of which was paid on or about December 31, 2025, and the remaining amounts in equal payments on or before March 31, 2026, and May 31, 2026. KBW had asserted that it was due $37.8 million in advisory fees connection with the Registered Offering and the Private Placement. The parties also generally released each other from all claims or other obligations in respect of the May 14, 2025, and June 16, 2025, agreements and any transactions related thereto.

 

Registration Rights Agreement

 

On or about August 11, 2025, the Company and the Lead Investor entered into a Registration Rights Agreement requiring a resale registration statement within 15 days after closing and effectiveness within the contractual deadline. The resale registration statement has not been filed. Section 2(d) provides liquidated damages of $1,000 per day of failure per Holder for specified registration failures. Amounts unpaid more than seven days after becoming payable bear interest at 18% per annum, subject to the maximum lawful rate.

 

Lock-Up Agreements

 

Pursuant to the Purchase Agreements, the Company will not issue, enter into any agreement to issue, or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock equivalents, or file any registration statement or any amendment or supplement thereto, for a period of 30 days after the Effective Date, subject to certain customary exceptions, including the use of the Sales Agreement (as defined herein), without the consent of the Purchasers, the Lead Investor and the Placement Agent.

 

25
 

 

In addition, each of the Company’s directors and executive officers are subject to a lock-up agreement, which prohibits them from offering for sale, pledging, announcing the intention to sell, selling, contracting to sell, granting any option, right or warrant to purchase, or otherwise transferring or disposing of, 50% of their shares of Common Stock or any securities convertible into or exercisable or exchangeable for shares of Common Stock for a period of 90 days following the Effective Date and the remaining 50% upon the later of ninety (90) days after the Effective Date or the effective date of the Stockholder Approval. It is contemplated that the lock-up agreements will not prohibit our directors and executive officers and the selling stockholder from transferring shares of our common stock for bona fide estate or tax planning purposes, subject to certain requirements, including that the transferee be subject to the same lock-up terms.

 

Note 16: Stockholders’ Equity

 

Common Stock: Our Articles of Incorporation authorize 2.0 billion shares of common stock that may be issued from time to time having such rights, powers, preferences and designations as the Board of Directors may determine. During the 13 weeks ended September 26, 2026, and September 27, 2025, no shares of common stock were issued in lieu of professional services.

 

During the 39 weeks ending September 26, 2026, the Company issued 12,670,257 shares of its common stock for the acquisition of Block Street.

 

During the 39 weeks ending September 27, 2025, the Company issued 100,000 shares of its common stock to one individual under the Company’s 2023 Equity Incentive Plan. The aggregate value of the shares at issuance was approximately $605,000.

 

During the 39 weeks ending September 27, 2025, the Company issued 17,511 shares of its common stock to a non-affiliated third-party in exchange for brokerage services rendered.

 

During the 39 weeks ending September 27, 2025, the Company issued an aggregate of 700,000 restricted stock units to Tony Isaac, the Company’s President. 350,000 of the restricted stock units were issued from the Company’s 2024 Plan and 350,000 were issued from the Company’s 2023 Plan. The aggregate value of the shares at issuance was approximately $1.4 million.

 

During the 39 weeks ending September 27, 2025, pursuant to the terms and conditions of a related party promissory note, the Company converted approximately $323,000 of obligations into 529,161 shares of the Company’s common stock (see Note 13).

 

During the quarter ended September 27, 2025, pursuant to the terms and conditions of a related party promissory note, the Company converted approximately $306,000 of obligations into 502,852 shares of the Company’s common stock (see Note 13).

 

On May 15, 2025, pursuant to the terms and conditions of a promissory note, the Company converted approximately $91,500 of obligations into150,000 shares of the Company’s common stock (see Note 13).

 

On May 9, 2025, the Company acquired Mswipe. As consideration under the acquisition, the Company issued 1,000,000 shares of its common stock to the sellers of Mswipe (see Note 3).

 

On May 2, 2025, the Company entered into a licensing agreement with a non-affiliated third party, pursuant to which the third party will provide software licensing and support to the Company. In connection with the agreement, the Company issued to the third party 300,000shares of its common stock.

 

During the year ended December 27, 2025, the Company issued 45,455 shares of its common stock related to the exercise of warrants under the Small Debenture (see Note 13).

 

On May 4, 2024, the Company entered into an Asset Purchase Agreement for the purchase of specified assets of an unaffiliated third party. In connection with this transaction, the Company tendered 5,000 shares of the Company’s Series V Convertible Preferred Stock. The conversion ratio of the Series V Convertible Preferred Stock is 1:120, meaning every one share of Series V Convertible Preferred Stock, if and when converted into shares of Common Stock, shall convert into 120 shares of Common Stock. On March 12, 2025, the unaffiliated third-party exercised all tendered shares of Series V Convertible Preferred Stock into 600,000 shares of the Company’s common stock.

 

On January 15, 2025, the Company entered into a six-month consulting agreement with a non-affiliated third-party, pursuant to which the third-party will provide a variety of corporate advisory services related to investment banking matters to the Company. In connection with the agreement, on January 15, 2025, the Company issued to the third-party 15,499 shares of its common stock.

 

As of September 26, 2026, and December 27, 2025, there were 139,958,768 and 126,474,169, respectively, of common stock issued and 139,836,511 and 126,474,169shares, respectively, of common stock outstanding, net of shares held in Treasury of 122,257 as of September 26, 2026.

 

26
 

 

Equity Offerings: The Company’s 2024 Plan, which was adopted by the Board in November 2024 and approved by the Stockholders’ at the 2024 annual meeting of stockholders, replaces the 2023 Plan, which replaced the 2016 Plan, which replaced the 2011 Plan. Under the 2024 Plan, the maximum aggregate number of shares, which may be subject to or delivered under Awards granted under the Plan is 2,800,000shares. Awards may be in the form of a Stock Award, Option, Stock Appreciation Right, Stock Unit, or Other Stock-based Award granted in accordance with the terms of the respective Plan. During the 13 weeks ended September 27, 2026, there were no grants under the 2024 Plan.

 

The Company’s 2023 Plan, which was adopted by the Board in August 2023 and approved by the Stockholders’ at the 2023 Annual Meeting of Stockholders, replaces the 2016 Plan, which replaced the 2011 Plan. Under the 2023 Plan, the maximum aggregate number of shares, which may be subject to or delivered under Awards granted under the Plan is two million (2,000,000) shares. Awards may be in the form of a Stock Award, Option, Stock Appreciation Right, Stock Unit, or Other Stock-based Award granted in accordance with the terms of the respective Plan. During the 39 weeks ended September 26, 2026, and September 27, 2025, the Company recognized $0 and $0 in share-based compensation expense related to the 908,852 RSU’s that were awarded and immediately vested.

 

The Company’s 2016 Plan authorizes the granting of awards in any of the following forms: (i) incentive stock options, (ii) nonqualified stock options, (iii) restricted stock awards, and (iv) restricted stock units, and expires on the earlier of October 28, 2026, or the date that all shares reserved under the 2016 Plan are issued or no longer available. On November 4, 2020, the Company amended the 2016 Plan to increase the issuance of common shares from 400,000 to 800,000. The vesting period is determined by the Board of Directors at the time of the stock option grant. As of September 26, 2026, and December 27, 2025, 100,000 options were outstanding under the 2016 Plan.

 

The Company’s 2011 Plan authorizes the granting of awards in any of the following forms: (i) stock options, (ii) stock appreciation rights, and (iii) other share-based awards, including but not limited to, restricted stock, restricted stock units or performance shares, and expired on the earlier of May 12, 2021, or the date that all shares reserved under the 2011 Plan are issued or no longer available. As of September 26, 2026, and December 27, 2025, 8,000 were outstanding under the 2011 Plan. No additional awards will be granted under the 2011 Plan.

 

The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option pricing model. There were no stock options granted during the 13 weeks ended September 26, 2026.

 

Additional information relating to all outstanding stock options is as follows:

 Schedule of Additional Information Relating to All Outstanding Stock Options

  

Options

Outstanding

  

Weighted

Average

Exercise

Price

  

Aggregate

Intrinsic

Value

  

Weighted

Average

Remaining

Contractual

Life

 
Outstanding at December 27, 2025  20,000  $      3.83  $—   4.7 
Outstanding at March 28, 2026  20,000  $3.83  $—   4.4 
Outstanding at June 27, 2026  20,000  $3.83  $—   4.2 
Outstanding at September 26, 2026  20,000  $3.83  $—   3.0 
Exercisable at September 26, 2026  20,000  $3.83  $—   3.0 

 

The Company recognized $0 and $0 in share-based compensation expense related to restricted stock units for the 13 weeks ended September 26, 2026, and September 27, 2025, respectively, and $0 and $0 for the 39 weeks ended September 26, 2026, and September 27, 2025, respectively.

 

As of September 26, 2026, the Company had no unrecognized share-based compensation expense associated with equity awards.

 

Series I Convertible Preferred Stock

 

Shares of Series I Preferred Stock are convertible into the Company’s common shares at a ratio of 100:1. No shares were converted during the 13 weeks ended September 26, 2026. As of September 26, 2026 and December 27, 2025, there were 12,500 shares and 17,000 shares of Series I Convertible Preferred Stock outstanding.

 

27
 

 

Series Q Convertible Preferred Stock

 

Shares of Series Q Preferred Stock are convertible into the Company’s common shares at a ratio of 1:1. No shares were converted during the 13 weeks ended September 26, 2026. As of September 26, 2026 and December 27, 2025, there were 867,387 shares and 925,212 shares of Series Q Convertible Preferred Stock outstanding.

 

Series S Preferred Stock

 

On December 28, 2022, the Company acquired Soin Therapeutics LLC, by way of a triangular merger. In connection with this transaction, with a potential value of up to $30.0 million, the Company tendered 100,000 shares of the Company’s Series S Convertible Preferred Stock. Shares of Series S Convertible Preferred Stock are convertible into the Company’s common shares at a ratio of 1:1. No shares were converted during the 13 weeks ended September 26, 2026. As of September 26, 2026, and December 27, 2025, there were 100,000 shares of Series S Convertible Preferred Stock outstanding.

 

Series V Convertible Preferred Stock

 

Shares of Series V Preferred Stock are convertible into the Company’s common shares at a ratio of 120:1. All outstanding shares of Series V Preferred Stock were converted into 600,000 shares of the Company’s common stock (see above). As of September 26, 2026, and December 27, 2025, there were 0 and 5,000 shares of Series V Convertible Preferred Stock outstanding, respectively.

 

Note 17: Mezzanine Equity

 

During the year ended December 28, 2024, the Company reclassified approximately $2.7 million from mezzanine equity to current liabilities and approximately $8.0 million to permanent equity. Series S consists of distinct contractual components of a single class of preferred shares: the $10.0 million component is carried at $8.0 million in permanent equity, and the $17.0 million convertible component is carried at $3.9 million in mezzanine equity. The two carrying amounts do not represent duplicate recognition of the same component. The class has 200,000 authorized shares and 100,000 shares issued and outstanding at September 26, 2026, and December 27, 2025; these shares are counted once.

 

Note 18: Earnings Per Share

 

Net income (loss) per share is calculated using the weighted average number of common shares outstanding during the applicable period. The 99,000,000 pre-funded warrants are excluded from the 2026 basic and diluted denominators because the warrants themselves had not been issued by September 26, 2026. Unvested restricted stock is excluded from basic weighted average shares. Potential common shares from ordinary warrants, stock options, restricted share awards and convertible preferred stock are included in diluted EPS only when dilutive and are excluded in the 2026 loss periods because their effect would be antidilutive.

 

The following table presents the computation of basic and diluted net income (loss) per share (in $000’s, except share and per–share data):

 Schedule of Computation of Basic and Diluted Net Loss Per Share

  September 26, 2026  September 27, 2025  September 26, 2026  September 27, 2025 
  For the Thirteen
Weeks Ended
  For the Thirty-Nine
Weeks Ended
 
  September 26, 2026  September 27, 2025  September 26, 2026  September 27, 2025 
Net income (loss) from continuing operations  (8,633)  47,308   (503,405)  41,568 
Net income (loss) from discontinued operations  (9,542)  1,654   (15,820)  (4,582)
Net income (loss) $(18,175) $48,962  $(519,225) $36,986 
Net income (loss) per share:                
Net income (loss) per share from continuing operations, basic $(0.06) $0.65  $(3.74) $1.17 
Net income (loss) per share from continuing operations, diluted $(0.06) $0.28  $(3.74) $0.31 
Net income (loss) per share from discontinued operations, basic $(0.07) $0.02  $(0.12) $(0.13)
Net income (loss) per share from discontinued operations, diluted $(0.07) $0.01  $(0.12) $(0.03)
Net income (loss) per share, basic $(0.13) $0.67  $(3.86) $1.04 
Net income (loss) per share, diluted $(0.13) $0.29  $(3.86) $0.28 
Weighted average common shares outstanding:                
Basic  139,836,511   72,887,313   134,429,846   35,662,862 
Diluted  139,836,511   168,657,684   134,429,846   132,041,354 

 

28
 

 

Potential common shares are excluded from diluted earnings per share when their effect would be antidilutive.

 

Note 19: Income Taxes

 

The Company recorded income tax benefits from continuing operations of approximately $4.2 million and $146.4 million for the thirteen and thirty-nine weeks ended September 26, 2026, respectively. The corresponding effective tax rates were approximately32.9% and 22.5%. The year-to-date continuing-operations benefit comprises approximately $4.3 million of current tax benefit and $146.4 million of deferred tax benefit. Income tax expense from discontinued operations was approximately $0.6 million and $0.5million for the thirteen and thirty-nine weeks ended September 26, 2026, respectively. The total year-to-date income tax benefit was approximately $146.4 million. For the thirteen and thirty-nine weeks ended September 27, 2025, income tax expense from continuing operations was approximately $13.3 million and $15.9 million, respectively, after reclassification of ALT5 Canada. Income tax benefits from discontinued operations were approximately $5.6 million and $5.4 million, respectively. Total consolidated tax expense remains $7.7 million and $10.5 million, respectively, consistent with the previously filed consolidated results.

 

Note 20: Segment Information

 

The following information separates continuing Fintech and Corporate and Other activities from discontinued ALT5 Canada and Biotechnology operations.

 

The following tables present revenue, cost of revenue, gross profit, selling, general and administrative expenses and operating income (loss) for the thirteen and thirty-nine weeks ended September 26, 2026, and September 27, 2025 (in thousands).

 Schedule of Segment Information

  Fintech  Corporate and Other  Discontinued operations  Total  Fintech  Corporate and Other  Discontinued operations  Total 
  13 Weeks Ended September 26, 2026  13 Weeks Ended September 27, 2025 
  Fintech  Corporate and Other  Discontinued operations  Total  Fintech  Corporate and Other  Discontinued operations  Total 
Revenue $248  $—  $596  $844  $913  $—  $6,662  $7,575 
Cost of revenue  160   —   20   180   465   —   4,487   4,952 
Gross profit  88   —   576   664   448   —   2,175   2,623 
Selling, general and administrative expenses  473   5,051   (84)

  5,440   448   12,118   8,645   21,211 
Operating income (loss)  (385)  (5,051)  660   (4,776)  —   (12,118)  (6,470)  (18,588)

 

  Fintech  Corporate and Other  Discontinued operations  Total  Fintech  Corporate and Other  Discontinued operations  Total 
  39 weeks Ended September26, 2026  39 weeks Ended September 27, 2025 
  Fintech  Corporate and Other  Discontinued operations  Total  Fintech  Corporate and Other  Discontinued operations  Total 
Revenue $934  $—  $7,035  $7,969  $1,235  $—  $18,232  $19,467 
Cost of revenue  388   —   989   1,377   789   —   10,689   11,478 
Gross profit  546   —   6,046   6,592   446   —   7,543   7,989 
Selling, general and administrative expenses  1,036   9,687   5,483   16,206   689   14,401   16,409   31,499 
Operating income (loss)  (490)  (9,687)  563   (9,614)  (243)  (14,401)  (8,866)  (23,510)

 

Note 21: Related Parties

 

Shared Services

 

Tony Isaac, the Company’s President, is the father of Jon Isaac, President and Chief Executive Officer of Live Ventures and managing member of Isaac Capital Group LLC (“ICG”). Tony Isaac is a member of the Board of Directors of Live Ventures. The Company also shares certain executive, accounting and legal services with Live Ventures. The total services shared were approximately $10,000and $30,000 for the 13 weeks ended September 26, 2026, and September 27, 2025, respectively, and $70,000 and $88,000 for the 39 weeks ended September 26, 2026, and September 27, 2025, respectively. ALT5 rents approximately 9,900 square feet of office space from Live Ventures in Las Vegas, Nevada.

 

Concrete Network Services Ltd. is owned by the chief technology officer of World Liberty Financial, whose chief executive officer is the chairman of the Company’s board. The pledged collateral, advance, expense, yield and loss-sharing commitments under this related-party arrangement are described in Note 8.

 

Note 22: Subsequent Events

 

The subsequent events described below reflect information available through November 10, 2026.

 

Fixed Deposits

 

Approximately $1,953,765 in Fixed Deposit notes matured on October 1, 2026. Of this total, Fixed Deposit notes with a face value of $1,110,885 were repaid on October 31, 2026 and Fixed Deposit notes with a face value of $842,880 were extended.

 

Margin call

 

Subsequent to September 26, 2026, the Company received a margin call in connection with the Concrete arrangement described in Note 8.

 

On November 5, 2026 the Company transferred a total of 343,400,000 WLFI tokens, with a fair market value of $15,260,696, to the wallets jointly controlled by Concrete and the Company.

 

29
 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) is intended to provide a reader of our financial statements with a narrative from the perspective of our management on our financial condition, results of operations, liquidity and certain other factors that may affect our future results. Dollars stated in thousands, except per–share amounts.

 

Forward-Looking and Cautionary Statements

 

This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of Exchange Act, which involve risks and uncertainties. You can identify forward-looking statements because they contain words such as ‘‘believes,’’ ‘‘expects,’’ ‘‘may,’’ ‘‘will,’’ ‘‘should,’’ ‘‘seeks,’’ ‘‘approximately,’’ ‘‘intends,’’ ‘‘plans,’’ ‘‘estimates’’ or ‘‘anticipates’’ or similar expressions that concern our strategy, plans or intentions. Any statements we make relating to our future operations, performance and results, and anticipated liquidity are forward-looking statements. All forward-looking statements are subject to risks and uncertainties that may change at any time, and, therefore, our actual results may differ materially from those we expected. We derive most of our forward-looking statements from our operating budgets and forecasts, which are based upon many detailed assumptions. While we believe that our assumptions are reasonable, we caution that it is very difficult to predict the impact of known factors, and, of course, it is impossible for us to anticipate all factors that could affect our actual results. Important factors that could cause actual results to differ materially from our expectations, including, without limitation, in conjunction with the forward-looking statements included in this Quarterly Report on Form 10-Q, are disclosed in “Item 1-Business, Item 1A – Risk Factors” of our Annual Report on Form 10-K for the fiscal year ended December 27, 2025, and Part II, Item 1A of this Report.

 

We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law. Our MD&A should be read in conjunction with our Form 10-K (including the information presented therein under the caption Risk Factors), together with our Quarterly Reports on Forms 10-Q and other publicly available information. All amounts herein are unaudited.

 

Our Company

 

Through our Fintech segment, we provide next generation blockchain-powered technologies to enable a migration to a new global financial paradigm, and, through our Biotechnology segment, we are focused on finding treatments for conditions that cause chronic pain and bringing to market drugs with non-addictive and non-sedative pain-relieving properties.

 

During the periods disclosed in this Quarterly Report, we operated three reportable segments:

 

Fintech

 

Our Fintech segment provides next generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and safe-keeping of digital assets. The Alt5 Canada portion of this segment is presented as discontinued operations for the 13 and 39 weeks ended September 26, 2026, and September 27, 2025.

 

Biotechnology

 

Our Biotechnology segment is focused on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. We have previously announced our intention to capitalize a subsidiary with certain of our biotechnology assets, acquire an additional biotechnology asset, and then engage in a financing of that subsidiary. The short-term intended result of that series of transactions would be for to decouple it from us so that it would operate on a stand-alone basis. The Biotech segment is being presented as discontinued operations for the 13 and 39 weeks ended September 26, 2026, and September 27, 2025. In connection with our previously announced, prospective spinoff of that subsidiary, we recently initiated serious discussions with two different public companies regarding a proposed transaction through which Drew would become a publicly traded entity. The terms currently under discussion contemplate a transaction valuation of Drew of approximately $200 million. Consummation of any spinoff transaction would be subject to the parties’ satisfactory completion of due diligence, negotiation, preparation, and execution and delivery of definitive agreements, and receipt of required regulatory and equity holder approvals, among other items. There can be no assurance that the parties will consummate any transaction at that estimated, approximate valuation, any other greater or lesser valuation, or at all.

 

Corporate and Other

 

In August 2025, we closed a $1.5 billion registered direct offering and concurrent private placement to launch our WLFI Treasury Strategy. This “capital with a purpose” financing positioned the Company as one of the most significant institutional holders of WLFI, securing a meaningful stake in the native governance token of the World Liberty Financial ecosystem.

 

Our policy remains a committed long-term “HODL” approach. We have successfully used our WLFI tokens as collateral for loans, enabling us to access cash while retaining exposure to the tokens. We expect to continue using eligible tokens as collateral to access cash, subject to applicable contractual restrictions, lender availability and collateral requirements. We are also in the process of taking advantage of new staking capabilities on the WLFI platform and expect to generate additional revenue from staking activities. The timing and amount of staking revenue will depend on the implementation of these activities and the platform’s terms and performance. Future acquisitions may also be funded through operating cash flows, structured debt and selective capital raises. Token sales remain restricted to liquidity requirements or material portfolio rebalancing events.

 

Our Corporate and Other segment consists of WLFI assets, including any additions, redemptions, or mark-to-market changes in value, are recorded within the Company’s Corporate and Other segment.

 

Our Corporate and Other segment consists of certain corporate general and administrative costs.

 

30
 

 

For the Thirteen Weeks Ended September 26, 2026 and September 27, 2025

 

Results of Operations

 

The following table presents selected operating results (in thousands). The 2025 comparisons have been recast to present ALT5 Canada and Biotechnology within discontinued operations.

 

  13 Weeks Ended  13 Weeks Ended 
  September 26, 2026  September 27, 2025 
Statement of Operations Data:        
Revenue $248  $913 
Gross profit  88   448 
Selling, general and administrative expenses  5,524   12,566 
Interest (expense), net  (469)  (359)
Unrealized loss on cryptocurrency assets  (3,841)  72,836 
Net loss from continuing operations before provision of income taxes  (12,867)  60,595 
Net loss from discontinued operations before provision of income taxes $(8,943) $(3,910)

 

The following tables present continuing-operations revenue and gross profit by business category (in thousands). Discontinued operations are excluded from the continuing totals.

 

  13 Weeks Ended  13 Weeks Ended 
  September 26, 2026  September 27, 2025 
  Net Revenue  Percent of Total  Net Revenue  Percent of Total 
Revenue                
Fintech $248   100% $913   100%
Corporate & Other  —   —%  —   —%
Discontinued operations  —   —%  —   —%
Total revenue $248   100% $913   100%

 

  13 Weeks Ended  13 Weeks Ended 
  September 26, 2026  September 27, 2025 
  Gross Profit  Gross Profit Percentage  Gross Profit  Gross Profit Percentage 
Gross Profit                
Fintech $88   35.5% $448   49.1%
Corporate & Other  —   —%  —   —%
Discontinued operations  —   —%  —   —%
Total gross profit $88   35.5% $448   49.1%

 

Revenue

 

Continuing-operations revenue decreased by approximately $0.7 million, or 72.8%, to $0.2 million for the 13 weeks ended September 26, 2026, from $0.9 million in the comparable 2025 period. The comparison reflects Mswipe within continuing operations and excludes the Alt5 Canada business disposed of during the quarter.

 

Gross Profit

 

Continuing-operations gross profit decreased by approximately $0.4 million to $0.1 million for the 13 weeks ended September 26, 2026, from $0.4 million in the comparable 2025 period. Gross margin decreased to 35.5% from 49.1%, reflecting the relationship between transaction revenue and related costs in the continuing business.

 

31
 

 

Selling, General and Administrative Expense

 

Continuing-operations selling, general and administrative expenses decreased by approximately $7.0 million to $5.5 million for the 13 weeks ended September 26, 2026, from $12.6 million on the recast 2025 basis. Current-period expenses comprise approximately $0.5 million for Fintech and $5.1 million for Corporate and Other. Fintech comprises Mswipe; Corporate and Other includes parent-company, digital-treasury and corporate/consolidating expenses.

 

Unrealized Loss on Cryptocurrency Assets

 

An unrealized loss on cryptocurrency assets of approximately $3.8 million was recorded for the 13 weeks ended September 26, 2026, compared with an unrealized gain of $72.8 million in the comparable 2025 period. The 2026 loss reflects the quarter’s change in the fair value of WLFI tokens and is a noncash item.

 

Other Income (Expense)

 

Other expense, net, was $3.2 million for the thirteen weeks ended September 26, 2026, compared with other income of $2,000 in the comparable 2025 period. The current-period amount includes a $0.9 million accumulated-deficit reconciliation adjustment recorded in continuing operations. Canada operating and disposal effects are presented in discontinued operations.

 

Segment Performance

 

The continuing businesses comprise Fintech and Corporate and Other. ALT5 Canada, sold in August 2026, and the Biotechnology business are presented within discontinued operations in the comparisons below.

 

Operating income or loss is measured before net interest, other income and expense, and income taxes. The Total columns below include the separately identified discontinued operations (in thousands).

 

  13 Weeks Ended September 26, 2026  13 Weeks Ended September 27, 2025 
  Fintech  Corporate and Other  Discontinued operations  Total  Fintech  Corporate and Other  Discontinued operations  Total 
Revenue $248  $—  $596  $844  $913  $—  $6,662  $7,575 
Cost of revenue  160   —   20   180   465   —   4,487   4,952 
Gross profit  88   —   576   664   448   —   2,175   2,623 
Selling, general and administrative expenses  473   5,051   (84)  5,440   448   12,118   8,645   21,211 
Operating income (loss)  (385)  (5,051)  660   (4,776)  —   (12,118)  (6,470)  (18,588)

 

Fintech Segment

 

Following the sale of ALT5 Canada, the continuing Fintech business consists of Mswipe. Continuing-operations revenue was approximately $0.2 million and gross profit was approximately $0.1 million for the 13 weeks ended September 26, 2026, with a gross margin of 35.5%.

 

Corporate and Other Segment

 

Corporate and Other generated no revenue in the 13-week periods ended September 26, 2026 and September 27, 2025. Its activities include corporate costs and the WLFI treasury program.

 

Discontinued Operations

 

Discontinued operations include ALT5 Canada and Biotechnology.

 

32
 

 

For the Thirty-Nine Weeks Ended September 26, 2026 and September 27, 2025

 

Results of Operations

 

The following table presents selected operating results (in thousands). The 2025 comparisons have been recast to present ALT5 Canada and Biotechnology within discontinued operations.

 

  39 weeks Ended  39 weeks Ended 
  September 26, 2026  September 27, 2025 
Statement of Operations Data:        
Revenue $934  $1,235 
Gross profit  546   446 
Selling, general and administrative expenses  10,723   15,090 
Interest expense, net  (1,000)  (858)
Unrealized loss on cryptocurrency assets  (637,222)  72,836 
Loss from continuing operations before provision of income taxes  (649,757)  57,490 
Loss from discontinued operations before provision of income taxes  (15,326)  (9,972)

 

The following tables present continuing-operations revenue and gross profit by business category (in thousands). Discontinued operations are excluded from the continuing totals.

 

  39 weeks Ended  39 weeks Ended 
  September 26, 2026  September 27, 2025 
  Net Revenue  Percent of Total  Net Revenue  Percent of Total 
Revenue                
Fintech $934   100% $1,235   100%
Corporate & Other  —   —%  —   —%
Discontinued operations  —   —%  —   —%
Total revenue $934   100% $1,235   100%

 

  39 weeks Ended  39 weeks Ended 
  September 26, 2026  September 27, 2025 
  Gross Profit  Gross Profit Percentage  Gross Profit  Gross Profit Percentage 
Gross Profit                
Fintech $546   58.5% $446   36.1%
Corporate & Other  —   —%  —   —%
Discontinued operations  —   —%  —   —%
Total gross profit $546   58.5% $446   36.1%

 

Revenue

 

Continuing-operations revenue decreased by approximately $0.3 million, or 24.4%, to $0.9 million for the 39 weeks ended September 26, 2026, from $1.2 million on the recast 2025 basis. Both periods exclude ALT5 Canada from continuing operations.

 

Gross Profit

 

Continuing-operations gross profit increased by approximately $0.1 million to $0.5 million for the 39 weeks ended September 26, 2026, from $0.4 million on the recast 2025 basis. Gross margin increased to 58.5% from 36.1%.

 

Selling, General and Administrative Expense

 

Continuing-operations selling, general and administrative expenses decreased by approximately $4.4 million to $10.7 million for the 39 weeks ended September 26, 2026, from $15.1 million on the recast 2025 basis. Current-period expenses comprise approximately $1.0 million for Fintech and $9.7 million for Corporate and Other.

 

33
 

 

Interest Expense, net

 

Net interest expense from continuing operations increased by approximately $0.1 million to $1.0 million for the 39 weeks ended September 26, 2026, from $0.9 million on the recast 2025 basis. This comparison excludes interest attributable to discontinued operations.

 

Unrealized Loss on Cryptocurrency Assets

 

An unrealized loss on cryptocurrency assets of approximately $637.2 million was recorded for the 39 weeks ended September 26, 2026, compared with an unrealized gain of $72.8 million in the comparable 2025 period. At September 26, 2026, the reported 7,283,585,650 WLFI tokens were valued at approximately $417.4 million using a closing price of $0.05731263 per token. The fair-value loss is noncash.

 

Other Income (Expense)

 

Other expense, net, was $1.6 million for the thirty-nine weeks ended September 26, 2026, compared with other expense of $78,000 in the comparable 2025 period. The year-to-date amount includes the reconciliation adjustment described above.

 

Segment Performance

 

The continuing businesses comprise Fintech and Corporate and Other. ALT5 Canada and Biotechnology are presented within discontinued operations for the periods compared below.

 

Operating income or loss is measured before net interest, other income and expense, and income taxes. The Total columns below include the separately identified discontinued operations (in thousands).

 

  39 weeks Ended September26 , 2026  39 weeks Ended September 27, 2025 
  Fintech  Corporate and Other  Discontinued operations  Total  Fintech  Corporate and Other  Discontinued operations  Total 
Revenue $934  $—  $7,035  $7,969  $1,235  $—  $18,232  $19,467 
Cost of revenue  388   —   989   1,377   789   —   10,689   11,478 
Gross profit  546   —   6,046   6,592   446   —   7,543   7,989 
Selling, general and administrative expenses  1,036   9,687   5,483   16,206   689   14,401   16,409   31,499 
Operating income (loss)  (490)  (9,687)  563   (9,614)  (243)  (14,401)  (8,866)  (23,510)

 

Fintech Segment

 

The continuing Fintech business consists of Mswipe. Continuing-operations revenue was approximately $0.9 million and gross profit was approximately $0.5 million for the 39 weeks ended September 26, 2026, with a gross margin of 58.5%.

 

Corporate and Other Segment

 

Corporate and Other generated no revenue in either 39-week period. Its activities include corporate costs and the WLFI treasury program.

 

Discontinued Operations

 

Discontinued operations include ALT5 Canada and Biotechnology.

 

Liquidity and Capital Resources

 

Overview

 

At September 26, 2026, cash was approximately $2.6 million, compared with opening consolidated cash of approximately $2.3 million. The Company also held a $1.3 million certificate of deposit, classified separately from cash. The cash bridge includes approximately $1.0 million of cash disposed of with ALT5 Canada. We have successfully obtained loans secured by WLFI tokens and expect to continue using eligible tokens as collateral to access cash, subject to contractual restrictions and collateral requirements. We are also pursuing new staking capabilities on the WLFI platform and expect additional revenue from those activities. Subsequent to quarter end, the Company received a margin call in connection with the Concrete arrangement as described in Note 22.

 

34
 

 

Cash Flows

 

Net cash used in operating activities was $21.0 million for the thirty-nine weeks ended September 26, 2026. Unrealized cryptocurrency losses of approximately $637.2 million and the deferred income tax benefit are noncash reconciliation items.

 

Net cash used in investing activities was $2.3 million. Investing cash flows comprise $5.0 million of certificate-of-deposit purchases, $3.7 million of principal redemptions and $1.0 million of cash disposed of with ALT5 Canada.

 

Net cash provided by financing activities was $16.7 million, comprising $18.0 million of borrowing proceeds, offset by $0.8 million of note repayments and $0.5 million of treasury-share purchases.

 

Future Sources of Cash; Phase 2b Trials, New Acquisitions, Products, and Services

 

We may require additional debt financing and/or capital to finance new acquisitions, conduct our Phase IIb clinical trials for our Biotechnology segment, or consummate other strategic investments in our business. No assurance can be given any financing obtained may not further dilute or otherwise impair the ownership interest of our existing stockholders.

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk

 

Market Risk and Impact of Inflation

 

Interest Rate Risk. We do not believe there is any significant risk related to interest rate fluctuations on our short and long-term fixed rate debt.

 

We do not hold any derivative financial instruments, nor do we hold any securities for trading or speculative purposes.

 

Item 4. Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

Evaluation of Disclosure control and Procedures. We carried out an evaluation, under the supervision, and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)). Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of September 26, 2026, the period covered in this report, our disclosure controls and procedures were not effective to ensure that information required to be disclosed in reports filed under the Exchange is recorded, processed, summarized and reported within the required time periods and is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure due to material weaknesses in internal control over financial reporting further described below.

 

Despite the identified material weaknesses, management concluded that the consolidated financial statements included in this Quarterly Report on Form 10-Q present fairly, in all material respects, the financial position, results of operations and cash flows for the periods disclosed in conformity with GAAP. LJ Soldinger Associates, LLC, the Company’s independent registered public accounting firm, issued an unqualified opinion on our consolidated financial statements as of and for the year ended December 27, 2025. They were not engaged to perform, and did not perform, an audit of internal control over financial reporting. The control deficiencies contributed to errors that required restatement of the Company’s 2024 consolidated financial statements, as described in the fiscal 2025 Annual Report on Form 10-K.

 

Management’s Report on Internal Control Over Financial Reporting. Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)). Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

35
 

 

The Company’s management, including our CEO and CFO, do not expect that the Company’s disclosure controls and procedures or the Company’s internal control over financial reporting will prevent or detect all errors and all fraud. A control system, regardless of how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system will be met. These inherent limitations include the following: judgments in decision-making can be faulty, and control and process breakdowns can occur because of simple errors or mistakes, controls can be circumvented by individuals, acting alone or in collusion with each other, or by management override. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected.

 

Our management assessed the effectiveness of our internal control over financial reporting as of September 26, 2026. In making this assessment, we used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) of 2013 regarding Internal Control – Integrated Framework. Based on our assessment using those criteria, our management concluded that our internal control over financial reporting were not effective as of September 26, 2026. Management noted the following deficiencies that management believes to be material weaknesses:

 

 ●The Company does not have a properly documented internal control system in accordance with the requirements of the Committee on Sponsoring Organizations (“COSO”) or some similarly appropriate internal control methodology or formal documentation of the Company’s systems of internal control. This control deficiency contributed to errors that necessitated a restatement of the Company’s 2024 consolidated financial statements and represents a material weakness in internal control over financial reporting.
   
 ●The Company did not properly apply ASC 820 in valuing certain equity instruments issued as consideration in a business combination. The Company recorded and adjustment to correct the error.

 

In response to the above identified weaknesses in our internal control over financial reporting, we plan to improve the documentation of our internal control policies and procedures and develop an internal testing plan to document our evaluation of effectiveness of the internal controls. We expect to conclude these remediation initiatives during the fiscal year ended December 26, 2026. We continue to evaluate testing of our internal control policies and procedures, including assessing internal and external resources that may be available to complete these tasks, but do not know when these tasks will be completed.

 

A material weakness (within the meaning of PCAOB Auditing Standard No. 5) is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. A significant deficiency is a deficiency, or a combination of deficiencies, in internal control over financial reporting that is less severe than a material weakness, yet important enough to merit attention by those responsible for oversight of the company’s financial reporting.

 

 ●The Company improperly recorded an adjustment that duplicated certain fees and overstated revenue. The Company recorded an adjustment to correct the error.
   
 ●The Company used an incorrect grant-date fair value in measuring certain equity awards. The amount of the misstatement was not material.
   
 ●The Company did not appropriately record certain qualifying equity issuance costs as a reduction of equity and instead recognized them in the income statement. The amount of the resulting misstatement was not material.

 

This Quarterly Report does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by our registered public accounting firm pursuant to temporary rules of the SEC that permit us to provide only management’s report in this Quarterly Report.

 

Changes in Internal Control Over Financial Reporting. There were no changes in the Company’s internal control over financial reporting identified in management’s evaluation pursuant to Rule 13a-15and 15d-15 of the Exchange Act that occurred during the period ended September 26, 2026 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

36
 

 

PART II. Other Information

 

Item 1. Legal Proceedings

 

The information in response to this item is included in Note 14, Commitments and Contingencies, to the Consolidated Financial Statements included in Part I, Item 1, of this Form 10-Q.

 

Item 1A. Risk Factors

 

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

 

Item 2. Unregistered Sales of Equity Securities and Use of funds

 

None.

 

Item 3. Defaults Upon Senior Securities

 

None.

 

Item 4. Mine Safety Disclosures

 

None.

 

Item 5. Other Information.

 

None.

 

Item 6. Exhibits.

 

Index to Exhibits

 

Exhibit

Number

 Exhibit Description Form 

File

Number

 

Exhibit

Number

 

Filing

Date

31.1*Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002        
           
31.2*Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002        
           
32.1*Certification of the President and Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002        
           
32.2*Certification of the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002        
           
101.INS*Inline XBRL Instance Document        
           
101.SCH*Inline XBRL Taxonomy Extension Schema Document        
           
101.CAL*Inline XBRL Taxonomy Extension Calculation Linkbase Document        
           
101.DEF*Inline XBRL Taxonomy Extension Definition Linkbase Document        
           
101.LAB*Inline XBRL Taxonomy Extension Label Linkbase Document        
           
101.PRE*Inline XBRL Taxonomy Extension Presentation Linkbase Document        
           
104 Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)        

 

* Filed herewith.

 

37
 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or Section 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on our behalf by the undersigned, thereunto duly authorized.

 

  AI Financial Corporation
  (Registrant)
    
Date: November 10, 2026By:/s/ Tony Isaac
   Tony Isaac
   Chief Executive Officer
   (Principal Executive Officer)
    
Date:November 10, 2026By:/s/Steven M. Plumb
   Steven M. Plumb
   Chief Financial Officer
   (Principal Financial and Accounting Officer)

 

38